🏷

Classifications

Harrison's Part

👪

Inheritance

1

Autosomal recessive HP:0000007

Classic GPS is autosomal recessive, with biallelic NBEAL2 variants — homozygous in about two thirds of pedigrees and compound heterozygous in the remainder. Heterozygous carriers may show a mild reduction in alpha-granule content without thrombocytopenia. Autosomal dominant (GFI1B) and X-linked (GATA1) disorders producing gray, agranular platelets exist but are distinct entities and are curated as differentials rather than as subtypes here.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:20709904 SUPPORT Human Clinical

"The mode of inheritance was autosomal recessive (AR) in 11 and indeterminate in 3 families."

Establishes the recessive mode across the pedigree series that mapped the locus.

◈

Mechanistic Hypotheses

3

NBEAL2 loss as a failure of cargo packaging and retention, not of granule cargo synthesis

cargo_packaging_failure_model CANONICAL

Evidence balance 2 support

The defect is downstream of synthesis. Megakaryocytes make alpha-granule proteins; what they cannot do is get them into, or keep them in, the developing granule. Two observations pin this down. Endogenously synthesized cargo (platelet factor 4, beta-thromboglobulin) is markedly reduced while endocytosed constituents are much less affected — exactly the asymmetry a packaging defect predicts and a synthesis defect does not. And in the mouse model, P-selectin is still present and externalized on activation and VPS33B/VPS16B levels are normal, placing NBEAL2 downstream of and independent from that trafficking axis, at a later stage of granule biogenesis.

Pathograph links

NBEAL2 Loss of Function -> Failure of Alpha-Granule Cargo Packaging DIRECT NBEAL2 acts within megakaryocytes at a late stage of alpha-granule biogenesis; its loss is the direct cause of the packaging failure.

Failure of Alpha-Granule Cargo Packaging -> Macrothrombocytopenia and Impaired Platelet Function DIRECT Absent granule cargo impairs adhesion, aggregation and coagulant activity, and abnormal granule formation disrupts megakaryocyte development and platelet production.

Show evidence (2 references)

PMID:21765412 SUPPORT Human Clinical

"In GPS, proteins synthesized in megakaryocytes are markedly reduced, while endocytosed α-granule constituents are less affected3. This suggests that GPS megakaryocytes fail to pack their endogeneously synthesized secretory proteins into developing α-granules."

The cargo-origin asymmetry that distinguishes a packaging failure from a synthesis failure.

PMID:23861251 SUPPORT Model Organism

"The presence of P-selectin and normal levels of VPS33B and VPS16B in Nbeal2(-/-) platelets suggests that NBEAL2 acts independently of VPS33B/VPS16B at a later stage of α-granule biogenesis."

Places NBEAL2's step in the pathway relative to a known trafficking axis, which is what makes this hypothesis specific.

Constitutive megakaryocyte cargo release into marrow stroma as the driver of myelofibrosis

megakaryocyte_leakage_myelofibrosis_model CANONICAL

Evidence balance 2 support

The best available explanation for the disorder's most consequential complication. Because cargo cannot be retained, proteins that should only be released on platelet activation are instead released constitutively from megakaryocytes into the marrow. Chronic exposure of stroma to fibrogenic growth factors — platelet-derived growth factor prominently — is the proposed route to progressive fibrosis, with splenomegaly following as compensatory extramedullary haematopoiesis. Curated as CANONICAL because it is the consensus account across the primary literature and the review, while noting that the basis of the myelofibrosis has been explicitly described as unknown and the growth-factor step is inference from the packaging defect rather than a demonstrated marrow measurement in patients.

Pathograph links

Failure of Alpha-Granule Cargo Packaging -> Constitutive Megakaryocyte Cargo Release into Marrow DIRECT Cargo that cannot be retained in the granule is released instead, which is the same lesion viewed from the marrow's side.

Constitutive Megakaryocyte Cargo Release into Marrow -> Progressive Myelofibrosis INDIRECT UNKNOWN INTERMEDIATES The step from chronic stromal exposure to established fibrosis is the proposed but unproven part of the model; the primary literature states explicitly that the basis of myelofibrosis remains unknown, so the edge is recorded with its intermediates unknown.

Progressive Myelofibrosis -> Splenomegaly and Extramedullary Haematopoiesis INDIRECT KNOWN INTERMEDIATES As fibrosis displaces marrow haematopoiesis, the spleen takes it up and enlarges.

Show evidence (2 references)

PMID:21765411 SUPPORT Human Clinical

"Proteins normally only released upon platelet activation are spontaneously released from MKs; most likely because of the lack of α-granules3."

States the constitutive megakaryocyte release that this hypothesis makes the driver of marrow fibrosis.

PMID:21765412 SUPPORT Human Clinical

"The basis of myelofibrosis remains unknown, but constitutive release of platelet-derived growth factor and other pro-fibrotic substances from megakaryocytes into the bone marrow may be involved5."

Gives the hypothesis in the authors' own hedged form, which is the epistemic status this entry preserves rather than overstating.

NBEAL2 as a general granule-biogenesis factor across blood lineages, with CTLA-4 mislocalization causing autoimmunity

pan_leukocyte_granule_defect_model CANONICAL

Evidence balance 3 support

GPS is not confined to platelets. Proteomic comparison across GPS platelets, neutrophils, monocytes, and CD4 lymphocytes found that the proteins depleted in each are enriched for granule constituents — one molecular defect expressed in four lineages. The autoimmune arm has its own mechanism: NBEAL2 co-immunoprecipitates with CTLA-4, and NBEAL2 deficiency lowers CTLA-4 expression in patient effector T cells while sparing regulatory T cells, with knockdown in healthy T cells reproducing the finding. The parallel with LRBA — the same BEACH-domain family, autoimmunity through defective CTLA-4 trafficking — is what makes this more than a correlation.

Pathograph links

NBEAL2 Loss of Function -> Leukocyte Granule Deficiency DIRECT NBEAL2 is expressed in neutrophils, monocytes and NK cells as well as megakaryocytes, so the same lesion produces granule deficits in those lineages directly rather than as a consequence of the platelet defect.

NBEAL2 Loss of Function -> Reduced Effector T Cell CTLA-4 Expression DIRECT NBEAL2 interacts with CTLA-4 directly by co-immunoprecipitation, and knockdown in healthy T cells reproduces the low expression.

Leukocyte Granule Deficiency -> Increased susceptibility to infection INDIRECT KNOWN INTERMEDIATES Reduced granule content and blunted NET formation are the proposed route to the modest excess of mild infection seen in patients; the mouse shows a much stronger version of the same link, with increased susceptibility to Staphylococcus aureus and murine CMV.

Reduced Effector T Cell CTLA-4 Expression -> Autoimmunity and Autoantibody Production INDIRECT KNOWN INTERMEDIATES Loss of an inhibitory checkpoint on effector T cells is the proposed route to the clinical autoimmunity, by analogy with LRBA deficiency; the step has not been demonstrated end to end in GPS patients.

Show evidence (3 references)

PMID:32693407 SUPPORT Human Clinical

"Proteins less abundant in these cells were enriched for constituents of granules, supporting a role for Nbeal2 in the function of these organelles across a wide range of blood cells."

The proteomic result that generalizes the granule defect beyond the megakaryocyte-platelet axis.

PMID:37349339 SUPPORT Human Clinical

"Interestingly, NBEAL2 deficiency leads to low CTLA-4 expression in patient-derived effector T cells, while their regulatory T cells appear unaffected."

The selective checkpoint defect that supplies a mechanism for the autoimmune phenotype.

PMID:37349339 SUPPORT In Vitro

"Knocking-down NBEAL2 in healthy primary T cells recapitulates the low CTLA-4 expression observed in the T cells of GPS patients."

The manipulation that rules out the low CTLA-4 being a consequence of chronic disease rather than of NBEAL2 loss.

?

Discussions and Knowledge Gaps

4

How does loss of NBEAL2 function mechanistically cause defective alpha-granule biogenesis?

KNOWLEDGE GAP gps_nbeal2_molecular_function_unknown

Attached to

pathophysiology#Failure of Alpha-Granule Cargo Packaging

The causal gene has been known since 2011 and the step it acts at has been bracketed - late in biogenesis, downstream of VPS33B/VPS16B - but the molecular function itself remains unstated. Its predicted interactors, WDFY3 and through it LYST, rest entirely on computational prediction, a limitation the gene-discovery paper states explicitly. This is a gap in molecular mechanism rather than in disease-gene assignment, and it is why the cargo-packaging node is necessarily described phenomenologically rather than as a pathway.

Proposed experiments

Proximity-labelling interactome of NBEAL2 in human megakaryocytes

exp_nbeal2_interactome

Use proximity-dependent biotinylation of tagged NBEAL2 in iPSC-derived human megakaryocytes to identify physical interactors at the dense tubular system, and test the predicted WDFY3 interaction directly. Replacing computationally predicted partners with measured ones is the prerequisite for any mechanistic model of the packaging step.

Show evidence (2 references)

PMID:21765412 SUPPORT Human Clinical

"How absence of NBEAL2 function in megakaryocytes results in defective α-granule biogenesis remains unknown."

The source's own statement of the gap.

PMID:21765412 SUPPORT Computational

"These protein-protein interactions are entirely based on computational predictions; future experiments will determine their accuracy."

Supports the caveat that the proposed interactome is unmeasured, which is what the proposed experiment addresses. COMPUTATIONAL because the interactome being described is network inference without wet-lab confirmation - which is the entire point of the item, so any other evidence_source would contradict the claim it exists to make.

Is marrow fibrosis in GPS actually caused by constitutive megakaryocyte release of fibrogenic cargo, or is that inference from the packaging defect?

KNOWLEDGE GAP gps_myelofibrosis_mechanism_unproven

Attached to

pathophysiology#Progressive Myelofibrosis

The leakage model is the consensus account and it is mechanistically natural, but the primary literature states plainly that the basis of the myelofibrosis remains unknown, and the fibrogenic-growth-factor step has not been demonstrated by direct marrow measurement in patients. The causal edge into this node is therefore recorded as having unknown intermediates. What would settle it is quantification of PDGF and TGF-beta in GPS marrow alongside fibrosis grade, or a fibrosis rescue in the knockout by blocking those factors. Two further points bear on why this has stayed open. First, a second, non-exclusive candidate exists and is rarely stated alongside the leakage model: microarray data in GPS fibroblasts showed overexpression of fibronectin, which is essential for proplatelet formation and critical for megakaryocyte-matrix interaction - a matrix mechanism rather than a cargo-release one. The two predict different things about whether suppressing megakaryocyte output would slow the fibrosis. Second, the obstacle is concrete rather than merely one of priority: the fibrotic marrow itself prevented the gene-discovery authors from harvesting enough megakaryocytes to culture, and megakaryocytes are the only cell type that expresses the packaging defect. That is why the mouse, which reproduces the splenomegaly and granule phenotype, is the natural system in which to test a hypothesis human tissue has resisted.

Show evidence (2 references)

PMID:21765412 SUPPORT In Vitro

"Our previous microarray data in GPS fibroblasts showed overexpression of fibronectin11, essential for proplatelet formation in cultured megakaryocytes12 and critical for megakaryocyte-matrix interactions13."

Supports the second, matrix-based candidate mechanism named in this gap, which the consensus leakage model does not subsume. IN_VITRO because the measurement is a microarray on cultured patient fibroblasts, not an observation in patients.

PMID:21765412 SUPPORT Human Clinical

"The fibrotic nature of the GPS bone marrow prevented us from obtaining sufficient bone marrow for ex-vivo expansion of GPS megakaryocytes, the only cell type that expresses the GPS phenotype of defective α-granule biogenesis."

Documents the specific methodological obstacle that has kept this gap open, and why a model system rather than patient tissue is the tractable route.

Should CTLA-4-Ig be trialled for autoimmune complications of GPS, and in which patients?

EMERGING HYPOTHESIS gps_ctla4_therapeutic_hypothesis

Attached to

pathophysiology#Reduced Effector T Cell CTLA-4 Expression

The mechanistic case is unusually clean for an ultra-rare disease: NBEAL2 binds CTLA-4, its loss lowers CTLA-4 on effector but not regulatory T cells, knockdown reproduces this in healthy T cells, and the closely related LRBA deficiency responds to CTLA-4-Ig. But no GPS patient has been reported treated this way, autoimmunity affects only a subset, and it is unknown whether CTLA-4 expression predicts who develops it. This is recorded as an emerging hypothesis with a licensed drug attached, not as a treatment.

Does the Nbeal2 knockout mouse model the human neutrophil phenotype, given that azurophilic granules are preserved in patients but reduced in the mouse?

HUMAN MODEL MISMATCH gps_mouse_neutrophil_granule_mismatch

Attached to

animal_models#Nbeal2 knockout mouse

The mouse reproduces the platelet lesion with high fidelity, which is why it carries the entry's model links. Its neutrophil phenotype is a different matter: azurophilic granules are described as preserved in human GPS but reduced in the knockout. Evidence therefore exists on both sides and disagrees, which makes this a translational-validity question rather than a gap — and it matters, because the innate-immune arm of GPS is exactly the part that the mouse is currently being used to study.

⚙

Pathophysiology

10

NBEAL2 Loss of Function

Biallelic loss-of-function variants in NBEAL2, a 54-exon gene on 3p21 encoding a 2754-amino-acid BEACH-domain scaffolding protein. The variant spectrum is broad — 86 different variants across 69 pedigrees, mostly private, comprising frameshift, nonsense, missense, splicing and small indels scattered along the gene — and no genotype-phenotype correlation has been demonstrated, either by mutation type or by position. That absence is itself informative: it argues the phenotype reflects loss of a single function rather than graded residual activity.

NBEAL2 as a general granule-biogenesis factor across blood lineages, with CTLA-4 mislocalization causing autoimmunity NBEAL2 loss as a failure of cargo packaging and retention, not of granule cargo synthesis

megakaryocyte CL:0000556

Downstream

Failure of Alpha-Granule Cargo Packaging NBEAL2 acts within megakaryocytes at a late stage of alpha-granule biogenesis; its loss is the direct cause of the packaging failure.

Leukocyte Granule Deficiency NBEAL2 is expressed in neutrophils, monocytes and NK cells as well as megakaryocytes, so the same lesion produces granule deficits in those lineages directly rather than as a consequence of the platelet defect.

Reduced Effector T Cell CTLA-4 Expression NBEAL2 interacts with CTLA-4 directly by co-immunoprecipitation, and knockdown in healthy T cells reproduces the low expression.

Show evidence (2 references)

PMID:21765413 SUPPORT Human Clinical

"Genomic DNA sequencing confirmed mutations in NBEAL2 as the genetic cause of GPS."

Establishes NBEAL2 as causal, from one of the three independent 2011 discovery papers.

PMID:34408521 SUPPORT Human Clinical

"Eighty-six different NBEAL2 variants have been detected in 69 GPS pedigrees described to date, harbouring homozygous (65%) or compound heterozygous (35%) mutations."

Quantifies the allelic heterogeneity and zygosity distribution recorded in this node.

Failure of Alpha-Granule Cargo Packaging

Megakaryocytes and platelets retain only rudimentary alpha-granule precursors. Endogenously synthesized cargo — platelet factor 4, von Willebrand factor, thrombospondin-1 — is markedly depleted, while endocytosed constituents are less affected, and dense granules, lysosomes, mitochondria and peroxisomes are preserved. That selectivity is what makes GPS an isolated alpha-storage pool disease rather than a general organelle defect.

Constitutive megakaryocyte cargo release into marrow stroma as the driver of myelofibrosis NBEAL2 loss as a failure of cargo packaging and retention, not of granule cargo synthesis

megakaryocyte CL:0000556 platelet CL:0000233

platelet alpha granule organization GO:0070889 ↓ DECREASED

platelet alpha granule GO:0031091

Animal models

Nbeal2 knockout mouse Mouse recapitulates Reproduces the core lesion — defective alpha-granule biogenesis in megakaryocytes with absence from platelets and loss of the specific cargo proteins depleted in patients.

Downstream

Macrothrombocytopenia and Impaired Platelet Function Absent granule cargo impairs adhesion, aggregation and coagulant activity, and abnormal granule formation disrupts megakaryocyte development and platelet production.

Constitutive Megakaryocyte Cargo Release into Marrow Cargo that cannot be retained in the granule is released instead, which is the same lesion viewed from the marrow's side.

Show evidence (2 references)

PMID:21765413 SUPPORT Human Clinical

"GPS is characterized by variable thrombocytopenia and large platelets that lack α-granules but have normal dense (δ) granules, lysosomes, mitochondria and peroxisomes1."

Establishes the selectivity of the defect for alpha-granules, which is the defining feature of this node.

PMID:23861251 SUPPORT Model Organism

"As in GPS, Nbeal2(-/-) mice exhibit splenomegaly, macrothrombocytopenia, and a deficiency of platelet α-granules and their cargo, including von Willebrand factor (VWF), thrombospondin-1, and platelet factor 4."

Names the specific depleted cargo proteins, reproduced in the knockout.

Constitutive Megakaryocyte Cargo Release into Marrow

Proteins that should be released only on platelet activation are instead released spontaneously from megakaryocytes into the marrow. The marrow stroma is therefore chronically exposed to factors it would normally see only transiently and locally at sites of vascular injury — among them platelet-derived growth factor and other pro-fibrotic substances.

Constitutive megakaryocyte cargo release into marrow stroma as the driver of myelofibrosis

megakaryocyte CL:0000556

bone marrow UBERON:0002371

Downstream

Progressive Myelofibrosis The step from chronic stromal exposure to established fibrosis is the proposed but unproven part of the model; the primary literature states explicitly that the basis of myelofibrosis remains unknown, so the edge is recorded with its intermediates unknown.

Show evidence (1 reference)

PMID:21765411 SUPPORT Human Clinical

"Proteins normally only released upon platelet activation are spontaneously released from MKs; most likely because of the lack of α-granules3."

Directly states the constitutive release this node describes.

Macrothrombocytopenia and Impaired Platelet Function

Platelets are reduced in number and enlarged, and — because the granule cargo needed for a robust platelet plug is missing — they function poorly at counts that would not normally cause bleeding. Median platelet count in the 47-patient international cohort era is moderate rather than profound thrombocytopenia, which is precisely why the functional deficit matters: the bleeding is disproportionate to the count. Impaired adhesion, aggregation and coagulant activity were demonstrated directly in the mouse model, together with defective arterial thrombus formation.

platelet CL:0000233

platelet degranulation GO:0002576 ↓ DECREASED

Animal models

Nbeal2 knockout mouse Mouse recapitulates Reproduces both the count/size phenotype and the functional deficit, and supplies the in vivo thrombosis readout that establishes the deficit is haemostatically consequential rather than only detectable ex vivo.

Downstream

Failure of Primary Hemostatic Plug Formation Too few platelets, and those that circulate cannot amplify haemostasis by secretion, so the plug fails to form or consolidate at the site of injury.

Show evidence (2 references)

PMID:21765411 SUPPORT Human Clinical

"Since the α-granule protein cargo is essential to the development of a robust platelet plug, GPS cases are symptomatic at platelet count levels that are typically not associated with bleeding."

States the disproportion between count and bleeding that defines this node.

PMID:23863626 SUPPORT Model Organism

"Nbeal2-deficient platelets displayed impaired adhesion, aggregation, and coagulant activity ex vivo that translated into defective arterial thrombus formation and protection from thrombo-inflammatory brain infarction following focal cerebral ischemia."

Direct functional measurement of the platelet deficit and its in vivo consequence.

Failure of Primary Hemostatic Plug Formation

The convergence node shared with the rest of the inherited platelet function disorders, reached here by the secretion route. Made explicit so this entry joins the family at the step the mechanism module treats as rate-limiting, and so that the disproportion the node above describes - bleeding at counts that would not normally cause it - has a place to land. Note that only the qualitative arm is routed through this node: the module deliberately does not model impaired platelet production, so the marrow and immune arms of this disorder reach their own consequences directly.

platelet CL:0000233

primary hemostasis GO:0007599 ↓ DECREASED

Downstream

Bleeding tendency Failure of platelet-dependent primary hemostasis presents as the mucocutaneous bleeding tendency.

Show evidence (2 references)

PMID:21781244 SUPPORT Human Clinical

"Genetic defects of platelet function give rise to mucocutaneous bleeding of varying severity because platelets fail to fulfil their haemostatic role after vessel injury."

Supports the convergence this node represents - a genetic platelet-function defect producing failure of the platelet's haemostatic role, and thence mucocutaneous bleeding of variable severity.

PMID:21765411 SUPPORT Human Clinical

"Since the α-granule protein cargo is essential to the development of a robust platelet plug, GPS cases are symptomatic at platelet count levels that are typically not associated with bleeding."

Ties the convergence specifically to this disorder - the missing granule cargo is what prevents a robust plug.

Progressive Myelofibrosis

Reticulin and collagen fibrosis of the marrow, developing over years to decades rather than being present from birth. It is the principal determinant of long-term morbidity, driving splenomegaly through compensatory extramedullary haematopoiesis and, in advanced disease, pancytopenia. Long-term follow-up established that the thrombocytopenia and the fibrosis are both progressive, and that the disorder can be fatal.

Constitutive megakaryocyte cargo release into marrow stroma as the driver of myelofibrosis

bone marrow UBERON:0002371

Downstream

Splenomegaly and Extramedullary Haematopoiesis As fibrosis displaces marrow haematopoiesis, the spleen takes it up and enlarges.

Show evidence (1 reference)

PMID:20709904 SUPPORT Human Clinical

"Long-term follow-up data demonstrated the progressive nature of the thrombocytopenia and myelofibrosis of GPS resulting in fatal hemorrhages in some patients."

Establishes both the progressive character of the fibrosis and that the disorder is not uniformly benign.

Splenomegaly and Extramedullary Haematopoiesis

Splenic enlargement, understood as compensatory extramedullary haematopoiesis in a marrow progressively replaced by fibrosis. It is a consistent feature of the human syndrome and is reproduced in the mouse knockout. Splenectomy improves but does not correct the platelet count, so it is not a routine recommendation.

spleen UBERON:0002106

Show evidence (1 reference)

PMID:20709904 SUPPORT Human Clinical

"GPS is associated with a bleeding tendency, myelofibrosis, and splenomegaly."

Establishes splenomegaly as a defining component of the syndrome alongside the fibrosis that drives it.

Leukocyte Granule Deficiency

The same biogenesis defect expressed outside the megakaryocyte lineage. In patients, neutrophils show reduced specific and gelatinase granule content with elevated surface and circulating granule proteins — the signature of inappropriate release rather than failed synthesis, since neutrophils differentiated in vitro from the same patients' progenitors have normal granule abundance — together with impaired extracellular trap formation, while azurophilic granules are preserved. The NK-cell defect is a separate claim with a separate evidence base: reduced numbers and impaired degranulation are established in Nbeal2-deficient mice, and whether the NK compartment is also altered in human GPS is explicitly an open question. Clinically the human picture is low leukocyte counts and a modest excess of mild infections rather than severe immunodeficiency.

NBEAL2 as a general granule-biogenesis factor across blood lineages, with CTLA-4 mislocalization causing autoimmunity

neutrophil CL:0000775 natural killer cell CL:0000623

neutrophil extracellular trap formation GO:0140645 ↓ DECREASED

Animal models

Nbeal2 knockout mouse Mouse partially recapitulates Reproduces the leukocyte arm — severe reduction in neutrophil granule content and dysfunctional NK cells with reduced degranulation — and supplies the infection-challenge data that cannot be obtained in patients.

Downstream

Increased susceptibility to infection Reduced granule content and blunted NET formation are the proposed route to the modest excess of mild infection seen in patients; the mouse shows a much stronger version of the same link, with increased susceptibility to Staphylococcus aureus and murine CMV.

Show evidence (6 references)

PMID:34408521 SUPPORT Human Clinical

"Low leukocyte counts, decreased neutrophil granulation and impaired neutrophil extracellular trap formation represent prominent findings in GPS patients, reflecting deranged innate immunity and associated with an increased susceptibility to infection."

Reports the neutrophil granule and NET deficits and their clinical correlate.

PMID:32693407 SUPPORT Human Clinical

"There were widespread differences in the transcriptome and proteome of GPS platelets, neutrophils, monocytes, and CD4 lymphocytes."

Establishes that the molecular disturbance spans four blood lineages rather than being platelet-restricted.

PMID:28783043 SUPPORT Model Organism

"Phenotyping of Nbeal2-deficient neutrophils showed a severe reduction in granule contents across all granule subsets."

The murine neutrophil granule phenotype. Note "all granule subsets" — in patients the azurophilic subset is preserved, which is the species divergence recorded in the HUMAN_MODEL_MISMATCH discussion.

+ 3 more references

Reduced Effector T Cell CTLA-4 Expression

NBEAL2 associates with CTLA-4 in primary T cells, and its loss lowers CTLA-4 expression in patient effector T cells while leaving regulatory T cells apparently unaffected — a selectivity that matters, since it removes a brake from the effector compartment specifically. The mechanism has a close precedent in LRBA, a BEACH-domain relative whose recessive loss causes autoimmunity through defective CTLA-4 trafficking.

NBEAL2 as a general granule-biogenesis factor across blood lineages, with CTLA-4 mislocalization causing autoimmunity

effector T cell CL:0000911

Downstream

Autoimmunity and Autoantibody Production Loss of an inhibitory checkpoint on effector T cells is the proposed route to the clinical autoimmunity, by analogy with LRBA deficiency; the step has not been demonstrated end to end in GPS patients.

Show evidence (1 reference)

PMID:37349339 SUPPORT In Vitro

"Investigating the potential association between NBEAL2 and CTLA-4 signalling suggested by the mass spectrometry results, we confirm by co-immunoprecipitation that CTLA-4 and NBEAL2 interact with each other."

The physical interaction underpinning this node. IN_VITRO because co-immunoprecipitation is a biochemical assay performed outside an organism; the patients supply the material, but the interaction is demonstrated on the bench, not observed clinically.

Autoimmunity and Autoantibody Production

A quarter of patients in the international cohort carried a diagnosed autoimmune disease and a majority tested positive for autoantibodies, with a plasma proteome shifted toward inflammation and immune response. This is the newest face of GPS and the reason the disorder is now framed as an immune as well as a haemostatic disease.

Show evidence (2 references)

PMID:32693407 SUPPORT Human Clinical

"Novel clinical phenotypes were also observed, including reduced leukocyte counts and increased presence of autoimmune disease and positive autoantibodies."

Establishes the autoimmune phenotype as a cohort-level finding rather than a case-report curiosity.

PMID:32693407 SUPPORT Human Clinical

"In summary, our data show that, in addition to the well-described platelet defects in GPS, there are immune defects. The abnormal immune cells may be the drivers of systemic abnormalities such as autoimmune disease."

The authors' framing of immune dysfunction as a second axis of the disease, which this entry adopts.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

8

Blood 1

Bleeding tendency VERY_FREQUENT Bruising susceptibility HP:0000978

Show evidence (3 references)

PMID:34408521 SUPPORT Human Clinical

"Most GPS patients are treated symptomatically, according to the severity of bleeding manifestations. Patients may bleed spontaneously or secondary to surgical intervention, childbirth or trauma."

Supports treating the bleeding tendency as a near-universal feature that varies in severity rather than in presence, which is the VERY_FREQUENT band.

PMID:20709904 SUPPORT Human Clinical

"GPS is associated with a bleeding tendency, myelofibrosis, and splenomegaly."

Establishes the bleeding tendency as a defining feature of the syndrome.

PMID:21765411 SUPPORT Human Clinical

"Gray platelet syndrome (GPS) is a predominantly recessive platelet disorder that is characterized by mild thrombocytopenia with large platelets and a paucity of α-granules; these abnormalities cause mostly moderate but in rare cases severe bleeding."

Gives the severity distribution — mostly moderate, rarely severe — recorded in this phenotype's description.

Cardiovascular 1

Splenomegaly HP:0001744

Show evidence (1 reference)

PMID:32693407 SUPPORT Human Clinical

"The GPS patient cohort exhibited known phenotypes, including macrothrombocytopenia, BM fibrosis, megakaryocyte emperipolesis of neutrophils, splenomegaly, and elevated serum vitamin B12 levels."

Ascertains splenomegaly in the international cohort.

Immune 2

Autoimmunity FREQUENT HP:0002960

Show evidence (2 references)

PMID:34408521 SUPPORT Human Clinical

"Autoimmune manifestations and/or autoantibodies (AutoAb) are present in around half of GPS patients, coupled to upregulation of immune response markers in CD4+ cells."

Supports the FREQUENT band (30-79%) for the combined autoimmunity/autoantibody phenotype.

PMID:34408521 SUPPORT Human Clinical

"Autoimmune diseases involving different organs and a spectrum of autoantibodies are present in a substantial proportion of GPS patients, expanding the syndromic spectrum of this disorder and pointing to dysregulation of the adaptive immune response."

Establishes the autoimmune phenotype and its interpretation as adaptive immune dysregulation.

Increased susceptibility to infection OCCASIONAL Recurrent infections HP:0002719

Show evidence (2 references)

PMID:34408521 SUPPORT Human Clinical

"recently reported to affect 17% of GPS patients in the large international cohort"

Supports the OCCASIONAL band (5-29%) for infection susceptibility in patients.

PMID:34408521 SUPPORT Human Clinical

"Low leukocyte counts, decreased neutrophil granulation and impaired neutrophil extracellular trap formation represent prominent findings in GPS patients, reflecting deranged innate immunity and associated with an increased susceptibility to infection."

Links the innate-immune granule defects to the infection susceptibility recorded here.

Other 4

Absence of platelet alpha-granules OBLIGATE Absence of alpha granules HP:0012526

Show evidence (1 reference)

PMID:21765412 SUPPORT Human Clinical

"the diagnosis is confirmed by electron microscopy (EM) showing absent or markedly reduced α-granules in platelets8(Fig. 1c-d) and in megakaryocytes9"

Supports the phenotype and its OBLIGATE frequency - it is the confirmatory diagnostic criterion, so no diagnosed patient lacks it.

Macrothrombocytopenia VERY_FREQUENT HP:0040185

Show evidence (2 references)

PMID:32693407 SUPPORT Human Clinical

"The GPS patient cohort exhibited known phenotypes, including macrothrombocytopenia, BM fibrosis, megakaryocyte emperipolesis of neutrophils, splenomegaly, and elevated serum vitamin B12 levels."

Ascertains macrothrombocytopenia as a known phenotype present in the 47-patient cohort, supporting the VERY_FREQUENT band for a defining feature of the syndrome.

PMID:34408521 SUPPORT Human Clinical

"Thrombocytopenia is a universal feature of GPS, being of moderate degree in most patients. In a recent study performed by Sims et al, which included the largest GPS cohort gathered to date, comprising 47 patients belonging to 38 pedigrees recruited worldwide, median platelet count was 57..."

Supports the VERY_FREQUENT band directly ("universal") and quantifies the degree, which is what makes the disproportion between count and bleeding a meaningful claim.

Bone marrow fibrosis FREQUENT Myelofibrosis HP:0011974

Course: PROGRESSIVE

Show evidence (2 references)

PMID:34408521 SUPPORT Human Clinical

"In a recent study, myelofibrosis was found in 58% of patients at a median age of 28.5 years (range, 10–52 years)."

Supports the FREQUENT band (30-79%) and gives the age distribution that makes this a delayed rather than a congenital feature.

PMID:20709904 SUPPORT Human Clinical

"Long-term follow-up data demonstrated the progressive nature of the thrombocytopenia and myelofibrosis of GPS resulting in fatal hemorrhages in some patients."

Supports both the phenotype and the PROGRESSIVE clinical course assigned to it.

Elevated serum vitamin B12 Elevated circulating vitamin B12 concentration HP:6000016

Show evidence (1 reference)

PMID:20709904 SUPPORT Human Clinical

"We identified high serum vitamin B(12) as a consistent, novel finding in GPS."

The primary report of this marker as a consistent feature.

🧬

Genetic Associations

1

NBEAL2

Gene: NBEAL2 hgnc:31928 relationship_type: CAUSATIVE

Autosomal recessive

Show evidence (2 references)

PMID:21765412 SUPPORT Human Clinical

"Here we show that mutations in NBEAL2 (neurobeachin-like 2), which encodes a BEACH/ARM/WD40 domain protein, cause GPS and that megakaryocytes and platelets from individuals with GPS express a unique combination of NBEAL2 transcripts."

Direct statement of causation from one of the three independent 2011 discovery papers.

PMID:34408521 SUPPORT Human Clinical

"No genotype-phenotype correlation has been demonstrated, either regarding the type of mutation or its location."

Records the absence of genotype-phenotype correlation, which constrains what genetic testing can predict clinically.

💊

Medical Actions

7

Platelet transfusion

Action: platelet transfusion Ontology label: Platelet Transfusion NCIT:C15366

The mainstay for active haemorrhage and for procedural cover. Because the need is lifelong, HLA-matched donor platelets are preferred where available to limit alloimmunization. It replaces the missing functional platelets rather than correcting anything upstream.

Mechanism Target:

BYPASSES Macrothrombocytopenia and Impaired Platelet Function — Transfused normal platelets supply the granule cargo and function the patient's own platelets lack, without altering the underlying defect — which is why the effect lasts only as long as the transfused platelets do.

Show evidence (1 reference)

PMID:21765411 SUPPORT Human Clinical

"Since the α-granule protein cargo is essential to the development of a robust platelet plug, GPS cases are symptomatic at platelet count levels that are typically not associated with bleeding."

Establishes that the deficit being bypassed is functional cargo, not merely platelet number.

Show evidence (1 reference)

PMID:34408521 SUPPORT Human Clinical

"Non-specific hemostatic measures, such as anti-fibrinolytics, local hemostatic measures, avoidance of non-steroidal anti-inflammatory drugs and/or platelet transfusions are usually adopted to prevent or reduce excessive bleeding."

Names platelet transfusion among the standard haemostatic measures in GPS.

Haematopoietic stem cell transplantation

Action: hematopoietic cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

The only reported curative option, and the only treatment in this entry that acts on the disease rather than on its consequences: transplantation replaces the NBEAL2-deficient haematopoietic compartment. It has been achieved in a GPS patient with severe myelofibrosis and pancytopenia, with full haematopoietic recovery and resolution of the marrow fibrosis — which is also the strongest available evidence that the fibrosis is driven by the haematopoietic cells rather than by an intrinsic stromal defect. It is curated as an option for selected patients with a severe course, not as standard care: the evidence is a single reported patient.

Mechanism Target:

RESTORES Progressive Myelofibrosis — Replacing the NBEAL2-deficient megakaryocyte compartment removes the source of the constitutive cargo release proposed to drive fibrosis; the reported resolution of marrow fibrosis after transplant is the closest thing to a test of that mechanism in a patient.

Show evidence (1 reference)

PMID:34408521 SUPPORT Human Clinical

"Successful hematopoietic stem cell transplantation has been achieved in a GPS patient with severe myelofibrosis and pancytopenia, with full hematopoietic recovery and resolution of bone marrow fibrosis."

Reports both the clinical outcome and the resolution of the fibrosis that this mechanism link asserts.

Show evidence (1 reference)

PMID:34408521 SUPPORT Human Clinical

"On this basis, stem cell transplantation may represent a curative treatment option for selected patients who experience a severe clinical course."

The review's own hedged recommendation, which is the strength this entry curates it at — a single patient, not a series.

Antifibrinolytic therapy

Action: Pharmacotherapy NCIT:C15986

Agent: tranexamic acid CHEBI:48669

Antifibrinolytics such as tranexamic acid are used to prevent or reduce bleeding, including around surgery and dental procedures. They stabilize the clot that the patient's granule-deficient platelets form poorly, rather than correcting the platelet defect.

Show evidence (1 reference)

PMID:34408521 SUPPORT Human Clinical

"Non-specific hemostatic measures, such as anti-fibrinolytics, local hemostatic measures, avoidance of non-steroidal anti-inflammatory drugs and/or platelet transfusions are usually adopted to prevent or reduce excessive bleeding."

Names antifibrinolytics among the standard haemostatic measures in GPS. The specific agent is not named by the source; tranexamic acid is bound here as the representative of the class.

Local haemostatic measures and avoidance of NSAIDs

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Local haemostatic measures for bleeding episodes, and avoidance of non-steroidal anti-inflammatory drugs, which add an acquired platelet function defect to the inherited one the patient already has. Curated separately from antifibrinolytic therapy because it is procedural and avoidance advice rather than a drug — the NSAID half is a genuine agents-to-avoid item, which the schema has no dedicated slot for.

Show evidence (1 reference)

PMID:34408521 SUPPORT Human Clinical

"Non-specific hemostatic measures, such as anti-fibrinolytics, local hemostatic measures, avoidance of non-steroidal anti-inflammatory drugs and/or platelet transfusions are usually adopted to prevent or reduce excessive bleeding."

Names local haemostatic measures and NSAID avoidance among the standard measures adopted in GPS.

Thrombopoietin receptor agonists (cautioned, not recommended)

Action: Pharmacotherapy NCIT:C15986

Curated as a caution rather than as a therapy. Eltrombopag raises platelet counts in several other inherited platelet disorders, which makes it an obvious thing to try here; its efficacy and safety in GPS are unknown, and because these agents may promote marrow fibrosis they collide directly with the complication that already defines this disease's long-term course. The entry records it so the reasoning is visible rather than leaving the apparent gap unexplained.

Show evidence (2 references)

PMID:34408521 NO_EVIDENCE Human Clinical

"The efficacy and safety of thrombopoietin receptor agonists in GPS remains unknown."

States the absence of evidence, which is the reason this is curated as a caution rather than as a treatment.

PMID:34408521 SUPPORT Human Clinical

"Considering that these agents may promote bone marrow fibrosis, their use in GPS should be viewed with caution, especially if long-term treatment is considered."

The disease-specific mechanistic reason for the caution: the drug class's known effect coincides with this disease's defining complication.

Splenectomy

Action: splenectomy Ontology label: Splenectomy NCIT:C15328

Performed in some patients for symptomatic splenomegaly. It produces at most a mild rise in platelet count and does not restore it, which is consistent with the entry's model of the thrombocytopenia: the falling count tracks marrow fibrosis rather than splenic sequestration, and removing the spleen therefore does not fix it.

Show evidence (1 reference)

PMID:34408521 SUPPORT Human Clinical

"Consistent with this notion, splenectomy may lead to mild increase but not complete restoration of platelet counts."

The limited effect, and the reasoning that makes it informative about where the thrombocytopenia comes from.

Genetic counselling

Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Recurrence risk for future pregnancies of carrier parents is 25%, and once a family's variants are known, carrier and prenatal testing become available. Counselling must also address the genetically distinct dominant (GFI1B) and X-linked (GATA1) disorders that produce a similar smear, since the recurrence risk differs entirely.

Show evidence (1 reference)

PMID:20709904 SUPPORT Human Clinical

"The mode of inheritance was autosomal recessive (AR) in 11 and indeterminate in 3 families."

The inheritance mode that determines the recurrence risk counselling rests on.

🔬

Biochemical Markers

1

Serum vitamin B12

Show evidence (1 reference)

PMID:20709904 SUPPORT Human Clinical

"We identified high serum vitamin B(12) as a consistent, novel finding in GPS."

The primary evidence for this marker's consistency in GPS.

🔬

Diagnosis

3

Peripheral blood smear and electron microscopy

Large, pale gray platelets on a stained smear are the diagnostic clue that names the disease; transmission electron microscopy showing absent or markedly reduced alpha-granules with preserved dense granules is the structural confirmation, and it is that contrast — alpha absent, dense preserved — that distinguishes GPS from the combined storage pool defects.

Show evidence (1 reference)

PMID:21765412 SUPPORT Human Clinical

"GPS platelets are large and appear gray on light microscopy (Fig. 1a-b)5-7; the diagnosis is confirmed by electron microscopy (EM) showing absent or markedly reduced α-granules in platelets8(Fig. 1c-d) and in megakaryocytes9, although both platelets and megakaryocytes have rudimentary α-granule..."

States the diagnostic sequence and the ultrastructural finding that confirms it.

NBEAL2 sequencing

Molecular confirmation, by targeted NBEAL2 sequencing when the phenotype is characteristic or by an inherited-platelet-disorder gene panel or exome when it is not. Because most variants are private and scattered across 54 exons, full-gene rather than hotspot analysis is required, and a normal panel does not exclude the diagnosis if the smear and electron microscopy are typical.

Show evidence (1 reference)

PMID:34408521 SUPPORT Human Clinical

"Genetic diagnosis may be approached by Sanger sequencing of the NBEAL2 gene, when the diagnosis of GPS is suspected based on the phenotypic features, or by high-throughput sequencing, including gene panels for inherited platelet disorders19 or whole-exome sequencing."

Describes the testing strategy recorded in this entry.

Bleeding severity does not track platelet count or function tests

A negative rule with direct management consequence: neither the platelet count nor functional test results predict how much a given patient will bleed, so laboratory values cannot be used to triage perioperative risk and a haemostatic plan has to be built for the individual.

Show evidence (1 reference)

PMID:31710726 SUPPORT Human Clinical

"Bleeding intensity does not correlate with platelet count nor with functional test results."

States the discordance directly, in a perioperative-management report.

📈

Progression

2

Bleeding-disorder phase

Macrothrombocytopenia and bleeding tendency are present from early life and are relatively stable; presentation is usually in infancy or childhood.

Show evidence (1 reference)

PMID:34408521 SUPPORT Human Clinical

"Typical clinical features include macrothrombocytopenia, bleeding and elevated vitamin B12 levels, while bone marrow fibrosis and splenomegaly may develop during disease progression."

Separates the early stable features from the later progressive ones, which is the distinction these two phases record.

Fibrotic phase

Marrow fibrosis and splenomegaly develop later and progress, with pancytopenia possible in advanced disease. This biphasic course is why lifelong surveillance is warranted even in patients whose bleeding is mild.

Show evidence (1 reference)

PMID:20709904 SUPPORT Human Clinical

"Long-term follow-up data demonstrated the progressive nature of the thrombocytopenia and myelofibrosis of GPS resulting in fatal hemorrhages in some patients."

Establishes the progressive character of this phase and its potential lethality.

📊

Prevalence

1

Worldwide

Cases In Literature <1 in 1,000,000

Ultra-rare. The scale is best conveyed by pedigree counts rather than a population rate: 86 NBEAL2 variants across 69 pedigrees had been described by the time of the 2021 review, and the largest single cohort comprised 47 patients. No incidence estimate exists.

Show evidence (1 reference)

PMID:34408521 SUPPORT Human Clinical

"Eighty-six different NBEAL2 variants have been detected in 69 GPS pedigrees described to date, harbouring homozygous (65%) or compound heterozygous (35%) mutations."

The pedigree count that stands in for a prevalence estimate in a disorder too rare for one.

⚖️

Clinical Burden

Moderate

Most patients have mild to moderate bleeding needing no specific treatment, which argues for a moderate rather than high assessment. Against that: the fibrotic phase is progressive and can end in marrow failure, fatal haemorrhage was documented on long-term follow-up, and the immune arm adds autoimmune disease in a quarter of patients. The burden is therefore moderate on average and materially higher in the subset that progresses.

Show evidence (2 references)

PMID:21765411 SUPPORT Human Clinical

"these abnormalities cause mostly moderate but in rare cases severe bleeding"

The bleeding-severity distribution underpinning the moderate assessment.

PMID:20709904 SUPPORT Human Clinical

"Long-term follow-up data demonstrated the progressive nature of the thrombocytopenia and myelofibrosis of GPS resulting in fatal hemorrhages in some patients."

The counterweight that keeps this from being scored as a low-burden disorder.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Gray Platelet Syndrome:

Chediak-Higashi Syndrome

Overlapping Features Caused by loss of LYST, another BEACH-domain vesicle-trafficking protein, and likewise a disorder of granule formation - but the affected organelles are lysosome-related (dense granules, cytotoxic granules, melanosomes), giving immunodeficiency, haemophagocytic lymphohistiocytosis and partial albinism with enlarged rather than absent granules. The domain kinship is real and is the reason the two are discussed together; the disease is not the same.

Show evidence (1 reference)

PMID:21765412 SUPPORT Human Clinical

"Another such protein is CHS1, which is defective in Chediak-Higashi disease (CHD, OMIM #214500), a disorder of immunodeficiency, platelet dense granule defects, partial albinism, and enlarged lysosomes or lysosome-related organelles in hematopoietic cells and melanocytes4,15."

States the shared protein family and the phenotypic differences that separate the two disorders.

Dense-Granule Storage Pool Disease and Combined Alpha-Delta SPD

Overlapping Features The storage pool diseases divide by which granule is lost. Isolated dense-granule deficiency (including the Hermansky-Pudlak and Chediak-Higashi syndromes) and combined alpha-delta deficiency are distinguished from this disorder by electron microscopy, not by the bleeding pattern.

Show evidence (1 reference)

PMID:21765412 SUPPORT Human Clinical

"Bleeding disorders arising from defective platelet granules constitute the platelet storage pool diseases (SPD) and include isolated δ -granule deficiency (delta-SPD), combined α and δ -SPD and isolated α -granule deficiency (GPS; OMIM #139090)3,4,6."

Sets out the storage pool disease classification that positions this disorder against its siblings.

ARC Syndrome (VPS33B/VIPAS39)

Overlapping Features Also produces defective alpha-granule biogenesis, but through the VPS33B/VPS16B machinery acting earlier in the pathway, and with arthrogryposis, renal dysfunction and cholestasis dominating the phenotype. The distinction matters mechanistically as well as clinically: it is what places NBEAL2's step late in biogenesis.

Show evidence (1 reference)

PMID:21781244 SUPPORT Human Clinical

"Defects of α-granule biosynthesis also involve germline VPS33B mutations in the ARC (arthrogryposis, renal dysfunction and cholestasis) syndrome."

Establishes the other genetic route to alpha-granule deficiency and the syndromic features that separate it.

🐁

Animal Models

1

Nbeal2 knockout mouse

The principal model, independently generated by more than one group with concordant results — including a spontaneous 8 bp Nbeal2 deletion found incidentally in an unrelated mutagenesis screen, which reproduces the same phenotype and so was not shaped by anyone's expectation of it. It reproduces the human syndrome closely — splenomegaly, macrothrombocytopenia, absent platelet alpha-granules and their cargo — and adds the functional measurements that cannot be made in patients: impaired adhesion, aggregation and coagulant activity translating into defective arterial thrombus formation, and abnormal megakaryocyte maturation, survival and ploidy.

Species

Mouse

Genotype

Nbeal2-/-

Publication

PMID:23863626

Pathograph links

Failure of Alpha-Granule Cargo Packaging recapitulates fidelity: high Reproduces the core lesion — defective alpha-granule biogenesis in megakaryocytes with absence from platelets and loss of the specific cargo proteins depleted in patients.

Limitations: One documented species difference matters for interpretation: azurophilic neutrophil granules are preserved in human GPS but reduced in the mouse, so the model overstates the neutrophil granule phenotype. Attributed to the review rather than curated as evidence here, since no citable primary comparison was established during curation.

Readouts

Platelet alpha-granule cargo content (VWF, thrombospondin-1, platelet factor 4)

Direction: DECREASED

Interpretation: Loss of the same cargo proteins depleted in patient platelets is the model's most direct correspondence to the human lesion.

Show evidence (1 reference)

PMID:23861251 SUPPORT Model Organism

"As in GPS, Nbeal2(-/-) mice exhibit splenomegaly, macrothrombocytopenia, and a deficiency of platelet α-granules and their cargo, including von Willebrand factor (VWF), thrombospondin-1, and platelet factor 4."

Reports the measurement and direction, with the human comparison stated.

Leukocyte Granule Deficiency partially recapitulates fidelity: moderate Reproduces the leukocyte arm — severe reduction in neutrophil granule content and dysfunctional NK cells with reduced degranulation — and supplies the infection-challenge data that cannot be obtained in patients.

Limitations: The reduction spans all neutrophil granule subsets in the mouse, whereas azurophilic granules are preserved in patients, so the model overstates the human neutrophil phenotype. The infection phenotype is also more severe: Nbeal2-deficient mice are susceptible to Staphylococcus aureus and murine CMV, while patients report mild respiratory infections rather than severe ones. NK involvement in human GPS is unestablished, so that half of the link is model-only.

Readouts

Neutrophil granule content across subsets

Direction: DECREASED

Interpretation: Granule depletion in a second lineage supports NBEAL2 acting as a general granule-biogenesis factor rather than a megakaryocyte-specific one.

Show evidence (1 reference)

PMID:28783043 SUPPORT Model Organism

"Phenotyping of Nbeal2-deficient neutrophils showed a severe reduction in granule contents across all granule subsets."

Reports the measurement and its direction, including the "all subsets" scope that diverges from the human phenotype.

NK cell degranulation

Direction: DECREASED

Interpretation: Impaired NK degranulation is the second lymphoid readout, and the one with no established human counterpart.

Show evidence (1 reference)

PMID:28783043 SUPPORT Model Organism

"Nbeal2-deficient NK cells were also dysfunctional and showed reduced degranulation."

Reports the NK functional deficit measured in the model.

Macrothrombocytopenia and Impaired Platelet Function recapitulates fidelity: high Reproduces both the count/size phenotype and the functional deficit, and supplies the in vivo thrombosis readout that establishes the deficit is haemostatically consequential rather than only detectable ex vivo.

Limitations: Murine bleeding assays and laser-induced arterial injury do not map onto the clinical bleeding phenotype (epistaxis, menorrhagia, post-procedural bleeding) in any quantitative way, so the model cannot be used to predict an individual patient's bleeding severity — which is also unpredictable from genotype in patients.

Readouts

Arterial thrombus formation on intravital imaging

Direction: DECREASED

Interpretation: Defective thrombus formation in vivo confirms the ex vivo platelet function deficit has haemostatic consequence.

Show evidence (1 reference)

PMID:23863626 SUPPORT Model Organism

"Nbeal2-deficient platelets displayed impaired adhesion, aggregation, and coagulant activity ex vivo that translated into defective arterial thrombus formation and protection from thrombo-inflammatory brain infarction following focal cerebral ischemia."

Reports the in vivo thrombosis readout and its ex vivo correlates.

Show evidence (2 references)

PMID:23863626 SUPPORT Model Organism

"Here we show that Nbeal2-knockout mice display the characteristics of human GPS, with defective α-granule biogenesis in MKs and their absence from platelets."

The authors' statement of phenotypic correspondence to the human disease, which is what licenses using this model for the entry's nodes.

PMID:26950939 SUPPORT Model Organism

"Mice homozygous for the Nbeal2 8 bp deletion (Nbeal2gps/gps) exhibit a phenotype similar to human GPS, with significantly reduced platelet counts compared to littermate controls (p = 1.63 x 10-7)."

An independently arising allele reproducing the phenotype, which is what supports the "more than one group, concordant results" claim in the description.

{ }

Source YAML

click to show

name: Gray Platelet Syndrome
creation_date: '2026-08-25T00:00:00Z'
category: Mendelian
synonyms:
- GPS
- grey platelet syndrome
- platelet alpha-granule deficiency
- alpha-storage pool deficiency
description: >-
  Gray platelet syndrome is an autosomal recessive inherited platelet disorder
  caused by biallelic loss-of-function variants in NBEAL2. Megakaryocytes
  synthesize alpha-granule cargo normally but cannot pack or retain it, so
  platelets emerge large, vacuolated, and — because the purple-staining granule
  content is gone — gray on a stained smear. The consequences are a bleeding
  tendency out of proportion to the platelet count, since the platelets that are
  present are also functionally impaired.

  The disorder is unusual in that its most serious complications are not
  haemostatic. Cargo that cannot be packaged is instead released
  constitutively from megakaryocytes into the marrow, and chronic exposure of
  marrow stroma to fibrogenic and pro-inflammatory factors is the leading
  explanation for the progressive myelofibrosis and consequent splenomegaly
  that develop over decades. Long-term follow-up of the original cohort
  documented that progression, including fatal haemorrhage in some patients,
  and identified a high serum vitamin B12 as a consistent biochemical marker.

  A second surprise arrived with the international cohort: NBEAL2 is expressed
  across haematopoietic lineages, and its loss is not confined to the
  megakaryocyte-platelet axis. Neutrophils show reduced granule content and
  impaired extracellular trap formation, NK cells are reduced and degranulate
  poorly, and a substantial minority of patients carry autoimmune disease or
  autoantibodies. The mechanism for that last observation is now partly
  understood: NBEAL2 interacts with CTLA-4, and its loss lowers CTLA-4
  expression selectively in effector T cells while sparing regulatory T cells —
  which is what makes CTLA-4-Ig a rational, though untried, therapeutic
  hypothesis. GPS is therefore better described as a granule-biogenesis
  disorder of blood cells than as a platelet disease.
disease_term:
  preferred_term: gray platelet syndrome
  term:
    id: MONDO:0007686
    label: gray platelet syndrome
parents:
- Inherited Platelet Disorder
classifications:
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
references:
- reference: PMID:32693407
  title: Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
- reference: PMID:34408521
  title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
inheritance:
- name: Autosomal recessive
  description: >-
    Classic GPS is autosomal recessive, with biallelic NBEAL2 variants —
    homozygous in about two thirds of pedigrees and compound heterozygous in
    the remainder. Heterozygous carriers may show a mild reduction in
    alpha-granule content without thrombocytopenia. Autosomal dominant
    (GFI1B) and X-linked (GATA1) disorders producing gray, agranular platelets
    exist but are distinct entities and are curated as differentials rather
    than as subtypes here.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mode of inheritance was autosomal recessive (AR) in 11 and
      indeterminate in 3 families.
    explanation: >-
      Establishes the recessive mode across the pedigree series that mapped the
      locus.
mechanistic_hypotheses:
- hypothesis_group_id: cargo_packaging_failure_model
  hypothesis_label: NBEAL2 loss as a failure of cargo packaging and retention, not of granule cargo synthesis
  status: CANONICAL
  description: >-
    The defect is downstream of synthesis. Megakaryocytes make alpha-granule
    proteins; what they cannot do is get them into, or keep them in, the
    developing granule. Two observations pin this down. Endogenously
    synthesized cargo (platelet factor 4, beta-thromboglobulin) is markedly
    reduced while endocytosed constituents are much less affected — exactly the
    asymmetry a packaging defect predicts and a synthesis defect does not. And
    in the mouse model, P-selectin is still present and externalized on
    activation and VPS33B/VPS16B levels are normal, placing NBEAL2 downstream of
    and independent from that trafficking axis, at a later stage of granule
    biogenesis.
  evidence:
  - reference: PMID:21765412
    reference_title: NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In GPS, proteins synthesized in megakaryocytes are markedly reduced, while
      endocytosed α-granule constituents are less affected3. This suggests that
      GPS megakaryocytes fail to pack their endogeneously synthesized secretory
      proteins into developing α-granules.
    explanation: >-
      The cargo-origin asymmetry that distinguishes a packaging failure from a
      synthesis failure.
  - reference: PMID:23861251
    reference_title: Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The presence of P-selectin and normal levels of VPS33B and VPS16B in
      Nbeal2(-/-) platelets suggests that NBEAL2 acts independently of
      VPS33B/VPS16B at a later stage of α-granule biogenesis.
    explanation: >-
      Places NBEAL2's step in the pathway relative to a known trafficking axis,
      which is what makes this hypothesis specific.
- hypothesis_group_id: megakaryocyte_leakage_myelofibrosis_model
  hypothesis_label: Constitutive megakaryocyte cargo release into marrow stroma as the driver of myelofibrosis
  status: CANONICAL
  description: >-
    The best available explanation for the disorder's most consequential
    complication. Because cargo cannot be retained, proteins that should only
    be released on platelet activation are instead released constitutively from
    megakaryocytes into the marrow. Chronic exposure of stroma to fibrogenic
    growth factors — platelet-derived growth factor prominently — is the
    proposed route to progressive fibrosis, with splenomegaly following as
    compensatory extramedullary haematopoiesis. Curated as CANONICAL because it
    is the consensus account across the primary literature and the review, while
    noting that the basis of the myelofibrosis has been explicitly described as
    unknown and the growth-factor step is inference from the packaging defect
    rather than a demonstrated marrow measurement in patients.
  evidence:
  - reference: PMID:21765411
    reference_title: Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Proteins normally only released upon platelet activation are spontaneously
      released from MKs; most likely because of the lack of α-granules3.
    explanation: >-
      States the constitutive megakaryocyte release that this hypothesis makes
      the driver of marrow fibrosis.
  - reference: PMID:21765412
    reference_title: NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The basis of myelofibrosis remains unknown, but constitutive release of
      platelet-derived growth factor and other pro-fibrotic substances from
      megakaryocytes into the bone marrow may be involved5.
    explanation: >-
      Gives the hypothesis in the authors' own hedged form, which is the
      epistemic status this entry preserves rather than overstating.
- hypothesis_group_id: pan_leukocyte_granule_defect_model
  hypothesis_label: NBEAL2 as a general granule-biogenesis factor across blood lineages, with CTLA-4 mislocalization causing autoimmunity
  status: CANONICAL
  description: >-
    GPS is not confined to platelets. Proteomic comparison across GPS
    platelets, neutrophils, monocytes, and CD4 lymphocytes found that the
    proteins depleted in each are enriched for granule constituents — one
    molecular defect expressed in four lineages. The autoimmune arm has its own
    mechanism: NBEAL2 co-immunoprecipitates with CTLA-4, and NBEAL2 deficiency
    lowers CTLA-4 expression in patient effector T cells while sparing
    regulatory T cells, with knockdown in healthy T cells reproducing the
    finding. The parallel with LRBA — the same BEACH-domain family, autoimmunity
    through defective CTLA-4 trafficking — is what makes this more than a
    correlation.
  evidence:
  - reference: PMID:32693407
    reference_title: Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Proteins less abundant in these cells were enriched for constituents of
      granules, supporting a role for Nbeal2 in the function of these organelles
      across a wide range of blood cells.
    explanation: >-
      The proteomic result that generalizes the granule defect beyond the
      megakaryocyte-platelet axis.
  - reference: PMID:37349339
    reference_title: NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Interestingly, NBEAL2 deficiency leads to low CTLA-4 expression in
      patient-derived effector T cells, while their regulatory T cells appear
      unaffected.
    explanation: >-
      The selective checkpoint defect that supplies a mechanism for the
      autoimmune phenotype.
  - reference: PMID:37349339
    reference_title: NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Knocking-down NBEAL2 in healthy primary T cells recapitulates the low CTLA-4
      expression observed in the T cells of GPS patients.
    explanation: >-
      The manipulation that rules out the low CTLA-4 being a consequence of
      chronic disease rather than of NBEAL2 loss.
pathophysiology:
- name: NBEAL2 Loss of Function
  conforms_to: "primary_hemostatic_plug_failure#Loss of a Platelet Primary-Hemostatic Component"
  biological_scale: MOLECULAR
  description: >-
    Biallelic loss-of-function variants in NBEAL2, a 54-exon gene on 3p21
    encoding a 2754-amino-acid BEACH-domain scaffolding protein. The variant
    spectrum is broad — 86 different variants across 69 pedigrees, mostly
    private, comprising frameshift, nonsense, missense, splicing and small
    indels scattered along the gene — and no genotype-phenotype correlation has
    been demonstrated, either by mutation type or by position. That absence is
    itself informative: it argues the phenotype reflects loss of a single
    function rather than graded residual activity.
  cell_types:
  - preferred_term: megakaryocyte
    term:
      id: CL:0000556
      label: megakaryocyte
  evidence:
  - reference: PMID:21765413
    reference_title: Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genomic DNA sequencing confirmed mutations in NBEAL2 as the genetic cause of
      GPS.
    explanation: >-
      Establishes NBEAL2 as causal, from one of the three independent 2011
      discovery papers.
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eighty-six different NBEAL2 variants have been detected in 69 GPS pedigrees
      described to date, harbouring homozygous (65%) or compound heterozygous
      (35%) mutations.
    explanation: >-
      Quantifies the allelic heterogeneity and zygosity distribution recorded in
      this node.
  downstream:
  - target: Failure of Alpha-Granule Cargo Packaging
    causal_link_type: DIRECT
    hypothesis_groups:
    - cargo_packaging_failure_model
    description: >-
      NBEAL2 acts within megakaryocytes at a late stage of alpha-granule
      biogenesis; its loss is the direct cause of the packaging failure.
  - target: Leukocyte Granule Deficiency
    causal_link_type: DIRECT
    hypothesis_groups:
    - pan_leukocyte_granule_defect_model
    description: >-
      NBEAL2 is expressed in neutrophils, monocytes and NK cells as well as
      megakaryocytes, so the same lesion produces granule deficits in those
      lineages directly rather than as a consequence of the platelet defect.
  - target: Reduced Effector T Cell CTLA-4 Expression
    causal_link_type: DIRECT
    hypothesis_groups:
    - pan_leukocyte_granule_defect_model
    description: >-
      NBEAL2 interacts with CTLA-4 directly by co-immunoprecipitation, and
      knockdown in healthy T cells reproduces the low expression.
- name: Failure of Alpha-Granule Cargo Packaging
  biological_scale: CELLULAR
  description: >-
    Megakaryocytes and platelets retain only rudimentary alpha-granule
    precursors. Endogenously synthesized cargo — platelet factor 4, von
    Willebrand factor, thrombospondin-1 — is markedly depleted, while
    endocytosed constituents are less affected, and dense granules, lysosomes,
    mitochondria and peroxisomes are preserved. That selectivity is what makes
    GPS an isolated alpha-storage pool disease rather than a general organelle
    defect.
  cell_types:
  - preferred_term: megakaryocyte
    term:
      id: CL:0000556
      label: megakaryocyte
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  cellular_components:
  - preferred_term: platelet alpha granule
    term:
      id: GO:0031091
      label: platelet alpha granule
  biological_processes:
  - preferred_term: platelet alpha granule organization
    term:
      id: GO:0070889
      label: platelet alpha granule organization
    modifier: DECREASED
  evidence:
  - reference: PMID:21765413
    reference_title: Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GPS is characterized by variable thrombocytopenia and large platelets that
      lack α-granules but have normal dense (δ) granules, lysosomes, mitochondria
      and peroxisomes1.
    explanation: >-
      Establishes the selectivity of the defect for alpha-granules, which is the
      defining feature of this node.
  - reference: PMID:23861251
    reference_title: Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      As in GPS, Nbeal2(-/-) mice exhibit splenomegaly, macrothrombocytopenia, and
      a deficiency of platelet α-granules and their cargo, including von
      Willebrand factor (VWF), thrombospondin-1, and platelet factor 4.
    explanation: >-
      Names the specific depleted cargo proteins, reproduced in the knockout.
  downstream:
  - target: Macrothrombocytopenia and Impaired Platelet Function
    causal_link_type: DIRECT
    hypothesis_groups:
    - cargo_packaging_failure_model
    description: >-
      Absent granule cargo impairs adhesion, aggregation and coagulant activity,
      and abnormal granule formation disrupts megakaryocyte development and
      platelet production.
  - target: Constitutive Megakaryocyte Cargo Release into Marrow
    causal_link_type: DIRECT
    hypothesis_groups:
    - megakaryocyte_leakage_myelofibrosis_model
    description: >-
      Cargo that cannot be retained in the granule is released instead, which is
      the same lesion viewed from the marrow's side.
- name: Constitutive Megakaryocyte Cargo Release into Marrow
  biological_scale: TISSUE
  description: >-
    Proteins that should be released only on platelet activation are instead
    released spontaneously from megakaryocytes into the marrow. The marrow
    stroma is therefore chronically exposed to factors it would normally see
    only transiently and locally at sites of vascular injury — among them
    platelet-derived growth factor and other pro-fibrotic substances.
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  cell_types:
  - preferred_term: megakaryocyte
    term:
      id: CL:0000556
      label: megakaryocyte
  evidence:
  - reference: PMID:21765411
    reference_title: Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Proteins normally only released upon platelet activation are spontaneously
      released from MKs; most likely because of the lack of α-granules3.
    explanation: >-
      Directly states the constitutive release this node describes.
  downstream:
  - target: Progressive Myelofibrosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - megakaryocyte_leakage_myelofibrosis_model
    description: >-
      The step from chronic stromal exposure to established fibrosis is the
      proposed but unproven part of the model; the primary literature states
      explicitly that the basis of myelofibrosis remains unknown, so the edge is
      recorded with its intermediates unknown.
- name: Macrothrombocytopenia and Impaired Platelet Function
  biological_scale: ORGANISM
  conforms_to: "primary_hemostatic_plug_failure#Impaired Platelet Activation, Granule Secretion, and Integrin Inside-Out Signalling"
  description: >-
    Platelets are reduced in number and enlarged, and — because the granule
    cargo needed for a robust platelet plug is missing — they function poorly
    at counts that would not normally cause bleeding. Median platelet count in
    the 47-patient international cohort era is moderate rather than profound
    thrombocytopenia, which is precisely why the functional deficit matters:
    the bleeding is disproportionate to the count. Impaired adhesion,
    aggregation and coagulant activity were demonstrated directly in the mouse
    model, together with defective arterial thrombus formation.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: platelet degranulation
    term:
      id: GO:0002576
      label: platelet degranulation
    modifier: DECREASED
  evidence:
  - reference: PMID:21765411
    reference_title: Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since the α-granule protein cargo is essential to the development of a
      robust platelet plug, GPS cases are symptomatic at platelet count levels
      that are typically not associated with bleeding.
    explanation: >-
      States the disproportion between count and bleeding that defines this node.
  - reference: PMID:23863626
    reference_title: Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Nbeal2-deficient platelets displayed impaired adhesion, aggregation, and
      coagulant activity ex vivo that translated into defective arterial thrombus
      formation and protection from thrombo-inflammatory brain infarction
      following focal cerebral ischemia.
    explanation: >-
      Direct functional measurement of the platelet deficit and its in vivo
      consequence.
  downstream:
  - target: Failure of Primary Hemostatic Plug Formation
    causal_link_type: DIRECT
    description: >-
      Too few platelets, and those that circulate cannot amplify haemostasis by
      secretion, so the plug fails to form or consolidate at the site of injury.
- name: Failure of Primary Hemostatic Plug Formation
  biological_scale: TISSUE
  conforms_to: "primary_hemostatic_plug_failure#Failure of Primary Hemostatic Plug Formation"
  description: >-
    The convergence node shared with the rest of the inherited platelet function
    disorders, reached here by the secretion route. Made explicit so this entry
    joins the family at the step the mechanism module treats as rate-limiting,
    and so that the disproportion the node above describes - bleeding at counts
    that would not normally cause it - has a place to land. Note that only the
    qualitative arm is routed through this node: the module deliberately does
    not model impaired platelet production, so the marrow and immune arms of
    this disorder reach their own consequences directly.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: primary hemostasis
    term:
      id: GO:0007599
      label: hemostasis
    modifier: DECREASED
  evidence:
  - reference: PMID:21781244
    reference_title: Advances in our understanding of the molecular basis of disorders of platelet function.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic defects of platelet function give rise to mucocutaneous bleeding of varying severity because platelets fail to fulfil their haemostatic role after vessel injury."
    explanation: >-
      Supports the convergence this node represents - a genetic platelet-function
      defect producing failure of the platelet's haemostatic role, and thence
      mucocutaneous bleeding of variable severity.
  - reference: PMID:21765411
    reference_title: Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since the α-granule protein cargo is essential to the development of a
      robust platelet plug, GPS cases are symptomatic at platelet count levels
      that are typically not associated with bleeding.
    explanation: >-
      Ties the convergence specifically to this disorder - the missing granule
      cargo is what prevents a robust plug.
  downstream:
  - target: Bleeding tendency
    causal_link_type: DIRECT
    description: >-
      Failure of platelet-dependent primary hemostasis presents as the
      mucocutaneous bleeding tendency.
- name: Progressive Myelofibrosis
  biological_scale: TISSUE
  description: >-
    Reticulin and collagen fibrosis of the marrow, developing over years to
    decades rather than being present from birth. It is the principal
    determinant of long-term morbidity, driving splenomegaly through
    compensatory extramedullary haematopoiesis and, in advanced disease,
    pancytopenia. Long-term follow-up established that the thrombocytopenia and
    the fibrosis are both progressive, and that the disorder can be fatal.
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  evidence:
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Long-term follow-up data demonstrated the progressive nature of the
      thrombocytopenia and myelofibrosis of GPS resulting in fatal hemorrhages in
      some patients.
    explanation: >-
      Establishes both the progressive character of the fibrosis and that the
      disorder is not uniformly benign.
  downstream:
  - target: Splenomegaly and Extramedullary Haematopoiesis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - megakaryocyte_leakage_myelofibrosis_model
    description: >-
      As fibrosis displaces marrow haematopoiesis, the spleen takes it up and
      enlarges.
- name: Splenomegaly and Extramedullary Haematopoiesis
  biological_scale: ORGANISM
  description: >-
    Splenic enlargement, understood as compensatory extramedullary
    haematopoiesis in a marrow progressively replaced by fibrosis. It is a
    consistent feature of the human syndrome and is reproduced in the mouse
    knockout. Splenectomy improves but does not correct the platelet count, so
    it is not a routine recommendation.
  locations:
  - preferred_term: spleen
    term:
      id: UBERON:0002106
      label: spleen
  evidence:
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GPS is associated with a bleeding tendency, myelofibrosis, and splenomegaly.
    explanation: >-
      Establishes splenomegaly as a defining component of the syndrome alongside
      the fibrosis that drives it.
- name: Leukocyte Granule Deficiency
  biological_scale: CELLULAR
  description: >-
    The same biogenesis defect expressed outside the megakaryocyte lineage.
    In patients, neutrophils show reduced specific and gelatinase granule
    content with elevated surface and circulating granule proteins — the
    signature of inappropriate release rather than failed synthesis, since
    neutrophils differentiated in vitro from the same patients' progenitors have
    normal granule abundance — together with impaired extracellular trap
    formation, while azurophilic granules are preserved. The NK-cell defect is
    a separate claim with a separate evidence base: reduced numbers and impaired
    degranulation are established in Nbeal2-deficient mice, and whether the NK
    compartment is also altered in human GPS is explicitly an open question.
    Clinically the human picture is low leukocyte counts and a modest excess of
    mild infections rather than severe immunodeficiency.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  biological_processes:
  - preferred_term: neutrophil extracellular trap formation
    term:
      id: GO:0140645
      label: neutrophil extracellular trap formation
    modifier: DECREASED
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Low leukocyte counts, decreased neutrophil granulation and impaired
      neutrophil extracellular trap formation represent prominent findings in GPS
      patients, reflecting deranged innate immunity and associated with an
      increased susceptibility to infection.
    explanation: >-
      Reports the neutrophil granule and NET deficits and their clinical
      correlate.
  - reference: PMID:32693407
    reference_title: Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There were widespread differences in the transcriptome and proteome of GPS
      platelets, neutrophils, monocytes, and CD4 lymphocytes.
    explanation: >-
      Establishes that the molecular disturbance spans four blood lineages rather
      than being platelet-restricted.
  - reference: PMID:28783043
    reference_title: NBEAL2 is required for neutrophil and NK cell function and pathogen defense.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Phenotyping of Nbeal2-deficient neutrophils showed a severe reduction in
      granule contents across all granule subsets.
    explanation: >-
      The murine neutrophil granule phenotype. Note "all granule subsets" — in
      patients the azurophilic subset is preserved, which is the species
      divergence recorded in the HUMAN_MODEL_MISMATCH discussion.
  - reference: PMID:28783043
    reference_title: NBEAL2 is required for neutrophil and NK cell function and pathogen defense.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Nbeal2-deficient NK cells were also dysfunctional and showed reduced
      degranulation.
    explanation: >-
      The NK-cell defect, in the mouse — the species this claim is scoped to.
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It would be interesting to study whether the NK compartment is also altered
      in human GPS.
    explanation: >-
      States that human NK status is unresolved, which is why the description
      scopes the NK claim to the mouse rather than to patients.
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Intriguingly, in contrast to GPS circulating neutrophils, neutrophils
      derived from in vitro differentiation of patient hematopoietic progenitors
      displayed normal abundance of specific granules, suggesting intact granule
      biosynthesis during granulopoiesis but lack of retention or premature
      exocytosis of specific granules during egress from the bone marrow or in
      the bloodstream.
    explanation: >-
      Distinguishes failed retention from failed synthesis in patient
      neutrophils — the same distinction the megakaryocyte arm of this entry
      rests on, reached independently in a different lineage.
  downstream:
  - target: Increased susceptibility to infection
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - pan_leukocyte_granule_defect_model
    description: >-
      Reduced granule content and blunted NET formation are the proposed route to
      the modest excess of mild infection seen in patients; the mouse shows a
      much stronger version of the same link, with increased susceptibility to
      Staphylococcus aureus and murine CMV.
- name: Reduced Effector T Cell CTLA-4 Expression
  biological_scale: MOLECULAR
  description: >-
    NBEAL2 associates with CTLA-4 in primary T cells, and its loss lowers CTLA-4
    expression in patient effector T cells while leaving regulatory T cells
    apparently unaffected — a selectivity that matters, since it removes a brake
    from the effector compartment specifically. The mechanism has a close
    precedent in LRBA, a BEACH-domain relative whose recessive loss causes
    autoimmunity through defective CTLA-4 trafficking.
  cell_types:
  - preferred_term: effector T cell
    term:
      id: CL:0000911
      label: effector T cell
  evidence:
  - reference: PMID:37349339
    reference_title: NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Investigating the potential association between NBEAL2 and CTLA-4 signalling
      suggested by the mass spectrometry results, we confirm by
      co-immunoprecipitation that CTLA-4 and NBEAL2 interact with each other.
    explanation: >-
      The physical interaction underpinning this node. IN_VITRO because
      co-immunoprecipitation is a biochemical assay performed outside an
      organism; the patients supply the material, but the interaction is
      demonstrated on the bench, not observed clinically.
  downstream:
  - target: Autoimmunity and Autoantibody Production
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - pan_leukocyte_granule_defect_model
    description: >-
      Loss of an inhibitory checkpoint on effector T cells is the proposed route
      to the clinical autoimmunity, by analogy with LRBA deficiency; the step
      has not been demonstrated end to end in GPS patients.
- name: Autoimmunity and Autoantibody Production
  biological_scale: ORGANISM
  description: >-
    A quarter of patients in the international cohort carried a diagnosed
    autoimmune disease and a majority tested positive for autoantibodies, with
    a plasma proteome shifted toward inflammation and immune response. This is
    the newest face of GPS and the reason the disorder is now framed as an
    immune as well as a haemostatic disease.
  evidence:
  - reference: PMID:32693407
    reference_title: Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Novel clinical phenotypes were also observed, including reduced leukocyte
      counts and increased presence of autoimmune disease and positive
      autoantibodies.
    explanation: >-
      Establishes the autoimmune phenotype as a cohort-level finding rather than
      a case-report curiosity.
  - reference: PMID:32693407
    reference_title: Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In summary, our data show that, in addition to the well-described platelet
      defects in GPS, there are immune defects. The abnormal immune cells may be
      the drivers of systemic abnormalities such as autoimmune disease.
    explanation: >-
      The authors' framing of immune dysfunction as a second axis of the disease,
      which this entry adopts.
phenotypes:
- category: Hematologic
  name: Absence of platelet alpha-granules
  description: >-
    The defining diagnostic finding, and the one the disorder is named for:
    platelets lack alpha-granules, which is why they appear grey on a routine
    May-Grunwald-Giemsa smear and why electron microscopy is confirmatory.
  phenotype_term:
    preferred_term: Absence of alpha granules
    term:
      id: HP:0012526
      label: Absence of alpha granules
  frequency: OBLIGATE
  evidence:
  - reference: PMID:21765412
    reference_title: "NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the diagnosis is confirmed by electron microscopy (EM) showing absent or markedly reduced α-granules in platelets8(Fig. 1c-d) and in megakaryocytes9"
    explanation: >-
      Supports the phenotype and its OBLIGATE frequency - it is the confirmatory
      diagnostic criterion, so no diagnosed patient lacks it.
- category: Hematologic
  name: Macrothrombocytopenia
  description: >-
    Reduced platelet count with enlarged platelets — moderate rather than
    profound thrombocytopenia, but accompanied by a functional defect, so
    bleeding occurs at counts that would otherwise be safe.
  phenotype_term:
    preferred_term: Macrothrombocytopenia
    term:
      id: HP:0040185
      label: Macrothrombocytopenia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:32693407
    reference_title: Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The GPS patient cohort exhibited known phenotypes, including
      macrothrombocytopenia, BM fibrosis, megakaryocyte emperipolesis of
      neutrophils, splenomegaly, and elevated serum vitamin B12 levels.
    explanation: >-
      Ascertains macrothrombocytopenia as a known phenotype present in the
      47-patient cohort, supporting the VERY_FREQUENT band for a defining
      feature of the syndrome.
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thrombocytopenia is a universal feature of GPS, being of moderate degree in
      most patients. In a recent study performed by Sims et al, which included
      the largest GPS cohort gathered to date, comprising 47 patients belonging
      to 38 pedigrees recruited worldwide, median platelet count was 57 (28–105)
      x 109/L.
    explanation: >-
      Supports the VERY_FREQUENT band directly ("universal") and quantifies the
      degree, which is what makes the disproportion between count and bleeding a
      meaningful claim.
- category: Hematologic
  name: Bleeding tendency
  description: >-
    Easy bruising, epistaxis, prolonged post-surgical and post-dental bleeding,
    and menorrhagia; intracranial haemorrhage is uncommon but occurs, and
    fatal haemorrhage was documented on long-term follow-up. Severity is
    variable and unpredictable from genotype.
  phenotype_term:
    preferred_term: Bruising susceptibility
    term:
      id: HP:0000978
      label: Bruising susceptibility
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most GPS patients are treated symptomatically, according to the severity of
      bleeding manifestations. Patients may bleed spontaneously or secondary to
      surgical intervention, childbirth or trauma.
    explanation: >-
      Supports treating the bleeding tendency as a near-universal feature that
      varies in severity rather than in presence, which is the VERY_FREQUENT
      band.
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GPS is associated with a bleeding tendency, myelofibrosis, and splenomegaly.
    explanation: >-
      Establishes the bleeding tendency as a defining feature of the syndrome.
  - reference: PMID:21765411
    reference_title: Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gray platelet syndrome (GPS) is a predominantly recessive platelet disorder
      that is characterized by mild thrombocytopenia with large platelets and a
      paucity of α-granules; these abnormalities cause mostly moderate but in rare
      cases severe bleeding.
    explanation: >-
      Gives the severity distribution — mostly moderate, rarely severe — recorded
      in this phenotype's description.
- category: Hematologic
  name: Bone marrow fibrosis
  description: >-
    Reticulin and collagen marrow fibrosis, absent early and accumulating over
    years to decades. It is the phenotype that converts GPS from a manageable
    bleeding disorder into a progressive haematological disease.
  phenotype_term:
    preferred_term: Myelofibrosis
    term:
      id: HP:0011974
      label: Myelofibrosis
    clinical_course: PROGRESSIVE
  frequency: FREQUENT
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In a recent study, myelofibrosis was found in 58% of patients at a median
      age of 28.5 years (range, 10–52 years).
    explanation: >-
      Supports the FREQUENT band (30-79%) and gives the age distribution that
      makes this a delayed rather than a congenital feature.
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Long-term follow-up data demonstrated the progressive nature of the
      thrombocytopenia and myelofibrosis of GPS resulting in fatal hemorrhages in
      some patients.
    explanation: >-
      Supports both the phenotype and the PROGRESSIVE clinical course assigned to
      it.
- category: Hematologic
  name: Splenomegaly
  description: >-
    Splenic enlargement secondary to marrow fibrosis and compensatory
    extramedullary haematopoiesis, occasionally severe enough to raise the
    question of splenectomy.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  evidence:
  - reference: PMID:32693407
    reference_title: Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The GPS patient cohort exhibited known phenotypes, including
      macrothrombocytopenia, BM fibrosis, megakaryocyte emperipolesis of
      neutrophils, splenomegaly, and elevated serum vitamin B12 levels.
    explanation: >-
      Ascertains splenomegaly in the international cohort.
- category: Hematologic
  name: Autoimmunity
  description: >-
    Diagnosed autoimmune disease in a substantial minority — thyroiditis,
    rheumatoid arthritis, discoid lupus, vitiligo, alopecia among them — with
    autoantibody positivity in a majority. Its mechanism is the CTLA-4 node,
    which makes this a phenotype with a candidate targeted therapy rather than
    an incidental association.
  phenotype_term:
    preferred_term: Autoimmunity
    term:
      id: HP:0002960
      label: Autoimmunity
  frequency: FREQUENT
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoimmune manifestations and/or autoantibodies (AutoAb) are present in
      around half of GPS patients, coupled to upregulation of immune response
      markers in CD4+ cells.
    explanation: >-
      Supports the FREQUENT band (30-79%) for the combined
      autoimmunity/autoantibody phenotype.
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoimmune diseases involving different organs and a spectrum of
      autoantibodies are present in a substantial proportion of GPS patients,
      expanding the syndromic spectrum of this disorder and pointing to
      dysregulation of the adaptive immune response.
    explanation: >-
      Establishes the autoimmune phenotype and its interpretation as adaptive
      immune dysregulation.
- category: Hematologic
  name: Elevated serum vitamin B12
  description: >-
    A near-universal and otherwise unexplained biochemical finding, identified
    as a novel and consistent marker on long-term follow-up of the original
    cohort. It is diagnostically useful precisely because it is not something
    one would predict from a platelet granule defect.
  phenotype_term:
    preferred_term: Elevated circulating vitamin B12 concentration
    term:
      id: HP:6000016
      label: Elevated circulating vitamin B12 concentration
  evidence:
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified high serum vitamin B(12) as a consistent, novel finding in
      GPS.
    explanation: >-
      The primary report of this marker as a consistent feature.
- category: Immunologic
  name: Increased susceptibility to infection
  description: >-
    A modest excess of mild infection — upper respiratory infections, otitis
    media — attributable to reduced neutrophil granule content, impaired NET
    formation, and NK-cell dysfunction. Severe infection is not characteristic,
    which is why this is curated as susceptibility rather than as an
    immunodeficiency.
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      recently reported to affect 17% of GPS patients in the large international
      cohort
    explanation: >-
      Supports the OCCASIONAL band (5-29%) for infection susceptibility in
      patients.
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Low leukocyte counts, decreased neutrophil granulation and impaired
      neutrophil extracellular trap formation represent prominent findings in GPS
      patients, reflecting deranged innate immunity and associated with an
      increased susceptibility to infection.
    explanation: >-
      Links the innate-immune granule defects to the infection susceptibility
      recorded here.
genetic:
- name: NBEAL2
  gene_term:
    preferred_term: NBEAL2
    term:
      id: hgnc:31928
      label: NBEAL2
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:21765412
    reference_title: NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we show that mutations in NBEAL2 (neurobeachin-like 2), which encodes a
      BEACH/ARM/WD40 domain protein, cause GPS and that megakaryocytes and
      platelets from individuals with GPS express a unique combination of NBEAL2
      transcripts.
    explanation: >-
      Direct statement of causation from one of the three independent 2011
      discovery papers.
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No genotype-phenotype correlation has been demonstrated, either regarding
      the type of mutation or its location.
    explanation: >-
      Records the absence of genotype-phenotype correlation, which constrains what
      genetic testing can predict clinically.
  notes: >-
    Heterozygous carriers may show a mild reduction in alpha-granule content
    without thrombocytopenia, so carrier status is not silent at the cellular
    level even though it is clinically silent.
biochemical:
- name: Serum vitamin B12
  notes: >-
    Characteristically elevated, in most patients well above the local upper
    reference limit. The mechanism is not established; increased transcobalamin
    release or turnover has been proposed. Useful as an ancillary diagnostic
    clue rather than as a disease-activity measure.
  biomarker_term:
    preferred_term: Serum vitamin B12 measurement
    term:
      id: NCIT:C64817
      label: Vitamin B12 Measurement
  evidence:
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified high serum vitamin B(12) as a consistent, novel finding in
      GPS.
    explanation: >-
      The primary evidence for this marker's consistency in GPS.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: BELOW_1_IN_1000000
  notes: >-
    Ultra-rare. The scale is best conveyed by pedigree counts rather than a
    population rate: 86 NBEAL2 variants across 69 pedigrees had been described
    by the time of the 2021 review, and the largest single cohort comprised 47
    patients. No incidence estimate exists.
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eighty-six different NBEAL2 variants have been detected in 69 GPS pedigrees
      described to date, harbouring homozygous (65%) or compound heterozygous
      (35%) mutations.
    explanation: >-
      The pedigree count that stands in for a prevalence estimate in a disorder
      too rare for one.
progression:
- phase: Bleeding-disorder phase
  notes: >-
    Macrothrombocytopenia and bleeding tendency are present from early life and
    are relatively stable; presentation is usually in infancy or childhood.
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Typical clinical features include macrothrombocytopenia, bleeding and
      elevated vitamin B12 levels, while bone marrow fibrosis and splenomegaly
      may develop during disease progression.
    explanation: >-
      Separates the early stable features from the later progressive ones, which
      is the distinction these two phases record.
- phase: Fibrotic phase
  notes: >-
    Marrow fibrosis and splenomegaly develop later and progress, with
    pancytopenia possible in advanced disease. This biphasic course is why
    lifelong surveillance is warranted even in patients whose bleeding is mild.
  evidence:
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Long-term follow-up data demonstrated the progressive nature of the
      thrombocytopenia and myelofibrosis of GPS resulting in fatal hemorrhages in
      some patients.
    explanation: >-
      Establishes the progressive character of this phase and its potential
      lethality.
clinical_burden:
  burden_level: MODERATE
  rationale: >-
    Most patients have mild to moderate bleeding needing no specific treatment,
    which argues for a moderate rather than high assessment. Against that: the
    fibrotic phase is progressive and can end in marrow failure, fatal
    haemorrhage was documented on long-term follow-up, and the immune arm adds
    autoimmune disease in a quarter of patients. The burden is therefore
    moderate on average and materially higher in the subset that progresses.
  evidence:
  - reference: PMID:21765411
    reference_title: Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      these abnormalities cause mostly moderate but in rare cases severe bleeding
    explanation: >-
      The bleeding-severity distribution underpinning the moderate assessment.
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Long-term follow-up data demonstrated the progressive nature of the
      thrombocytopenia and myelofibrosis of GPS resulting in fatal hemorrhages in
      some patients.
    explanation: >-
      The counterweight that keeps this from being scored as a low-burden
      disorder.
diagnosis:
- name: Peripheral blood smear and electron microscopy
  description: >-
    Large, pale gray platelets on a stained smear are the diagnostic clue that
    names the disease; transmission electron microscopy showing absent or
    markedly reduced alpha-granules with preserved dense granules is the
    structural confirmation, and it is that contrast — alpha absent, dense
    preserved — that distinguishes GPS from the combined storage pool defects.
  evidence:
  - reference: PMID:21765412
    reference_title: NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GPS platelets are large and appear gray on light microscopy (Fig. 1a-b)5-7;
      the diagnosis is confirmed by electron microscopy (EM) showing absent or
      markedly reduced α-granules in platelets8(Fig. 1c-d) and in megakaryocytes9,
      although both platelets and megakaryocytes have rudimentary α-granule
      precursors10.
    explanation: >-
      States the diagnostic sequence and the ultrastructural finding that confirms
      it.
- name: NBEAL2 sequencing
  description: >-
    Molecular confirmation, by targeted NBEAL2 sequencing when the phenotype is
    characteristic or by an inherited-platelet-disorder gene panel or exome when
    it is not. Because most variants are private and scattered across 54 exons,
    full-gene rather than hotspot analysis is required, and a normal panel does
    not exclude the diagnosis if the smear and electron microscopy are typical.
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic diagnosis may be approached by Sanger sequencing of the NBEAL2 gene,
      when the diagnosis of GPS is suspected based on the phenotypic features, or
      by high-throughput sequencing, including gene panels for inherited platelet
      disorders19 or whole-exome sequencing.
    explanation: >-
      Describes the testing strategy recorded in this entry.
- name: Bleeding severity does not track platelet count or function tests
  description: >-
    A negative rule with direct management consequence: neither the platelet
    count nor functional test results predict how much a given patient will
    bleed, so laboratory values cannot be used to triage perioperative risk and
    a haemostatic plan has to be built for the individual.
  evidence:
  - reference: PMID:31710726
    reference_title: "Gray platelet syndrome: Management of perioperative bleeding in redo cardiac surgery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bleeding intensity does not correlate with platelet count nor with functional test results."
    explanation: >-
      States the discordance directly, in a perioperative-management report.
treatments:
- name: Platelet transfusion
  description: >-
    The mainstay for active haemorrhage and for procedural cover. Because the
    need is lifelong, HLA-matched donor platelets are preferred where available
    to limit alloimmunization. It replaces the missing functional platelets
    rather than correcting anything upstream.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: platelet transfusion
    term:
      id: NCIT:C15366
      label: Platelet Transfusion
  target_mechanisms:
  - target: Macrothrombocytopenia and Impaired Platelet Function
    treatment_effect: BYPASSES
    description: >-
      Transfused normal platelets supply the granule cargo and function the
      patient's own platelets lack, without altering the underlying defect —
      which is why the effect lasts only as long as the transfused platelets do.
    evidence:
    - reference: PMID:21765411
      reference_title: Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Since the α-granule protein cargo is essential to the development of a
        robust platelet plug, GPS cases are symptomatic at platelet count levels
        that are typically not associated with bleeding.
      explanation: >-
        Establishes that the deficit being bypassed is functional cargo, not
        merely platelet number.
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non-specific hemostatic measures, such as anti-fibrinolytics, local
      hemostatic measures, avoidance of non-steroidal anti-inflammatory drugs
      and/or platelet transfusions are usually adopted to prevent or reduce
      excessive bleeding.
    explanation: >-
      Names platelet transfusion among the standard haemostatic measures in GPS.
  notes: >-
    No controlled trial or GPS-specific outcome data exists for transfusion; the
    evidence attached is a review statement of standard practice, not an
    efficacy result.
- name: Haematopoietic stem cell transplantation
  description: >-
    The only reported curative option, and the only treatment in this entry that
    acts on the disease rather than on its consequences: transplantation
    replaces the NBEAL2-deficient haematopoietic compartment. It has been
    achieved in a GPS patient with severe myelofibrosis and pancytopenia, with
    full haematopoietic recovery and resolution of the marrow fibrosis — which
    is also the strongest available evidence that the fibrosis is driven by the
    haematopoietic cells rather than by an intrinsic stromal defect. It is
    curated as an option for selected patients with a severe course, not as
    standard care: the evidence is a single reported patient.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Progressive Myelofibrosis
    treatment_effect: RESTORES
    description: >-
      Replacing the NBEAL2-deficient megakaryocyte compartment removes the
      source of the constitutive cargo release proposed to drive fibrosis; the
      reported resolution of marrow fibrosis after transplant is the closest
      thing to a test of that mechanism in a patient.
    evidence:
    - reference: PMID:34408521
      reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Successful hematopoietic stem cell transplantation has been achieved in a
        GPS patient with severe myelofibrosis and pancytopenia, with full
        hematopoietic recovery and resolution of bone marrow fibrosis.
      explanation: >-
        Reports both the clinical outcome and the resolution of the fibrosis that
        this mechanism link asserts.
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On this basis, stem cell transplantation may represent a curative treatment
      option for selected patients who experience a severe clinical course.
    explanation: >-
      The review's own hedged recommendation, which is the strength this entry
      curates it at — a single patient, not a series.
- name: Antifibrinolytic therapy
  description: >-
    Antifibrinolytics such as tranexamic acid are used to prevent or reduce
    bleeding, including around surgery and dental procedures. They stabilize
    the clot that the patient's granule-deficient platelets form poorly, rather
    than correcting the platelet defect.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tranexamic acid
      term:
        id: CHEBI:48669
        label: tranexamic acid
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non-specific hemostatic measures, such as anti-fibrinolytics, local
      hemostatic measures, avoidance of non-steroidal anti-inflammatory drugs
      and/or platelet transfusions are usually adopted to prevent or reduce
      excessive bleeding.
    explanation: >-
      Names antifibrinolytics among the standard haemostatic measures in GPS.
      The specific agent is not named by the source; tranexamic acid is bound
      here as the representative of the class.
- name: Local haemostatic measures and avoidance of NSAIDs
  description: >-
    Local haemostatic measures for bleeding episodes, and avoidance of
    non-steroidal anti-inflammatory drugs, which add an acquired platelet
    function defect to the inherited one the patient already has. Curated
    separately from antifibrinolytic therapy because it is procedural and
    avoidance advice rather than a drug — the NSAID half is a genuine
    agents-to-avoid item, which the schema has no dedicated slot for.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non-specific hemostatic measures, such as anti-fibrinolytics, local
      hemostatic measures, avoidance of non-steroidal anti-inflammatory drugs
      and/or platelet transfusions are usually adopted to prevent or reduce
      excessive bleeding.
    explanation: >-
      Names local haemostatic measures and NSAID avoidance among the standard
      measures adopted in GPS.
- name: Thrombopoietin receptor agonists (cautioned, not recommended)
  description: >-
    Curated as a caution rather than as a therapy. Eltrombopag raises platelet
    counts in several other inherited platelet disorders, which makes it an
    obvious thing to try here; its efficacy and safety in GPS are unknown, and
    because these agents may promote marrow fibrosis they collide directly with
    the complication that already defines this disease's long-term course. The
    entry records it so the reasoning is visible rather than leaving the
    apparent gap unexplained.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The efficacy and safety of thrombopoietin receptor agonists in GPS remains
      unknown.
    explanation: >-
      States the absence of evidence, which is the reason this is curated as a
      caution rather than as a treatment.
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Considering that these agents may promote bone marrow fibrosis, their use
      in GPS should be viewed with caution, especially if long-term treatment is
      considered.
    explanation: >-
      The disease-specific mechanistic reason for the caution: the drug class's
      known effect coincides with this disease's defining complication.
- name: Splenectomy
  description: >-
    Performed in some patients for symptomatic splenomegaly. It produces at most
    a mild rise in platelet count and does not restore it, which is consistent
    with the entry's model of the thrombocytopenia: the falling count tracks
    marrow fibrosis rather than splenic sequestration, and removing the spleen
    therefore does not fix it.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: splenectomy
    term:
      id: NCIT:C15328
      label: Splenectomy
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Consistent with this notion, splenectomy may lead to mild increase but not
      complete restoration of platelet counts.
    explanation: >-
      The limited effect, and the reasoning that makes it informative about where
      the thrombocytopenia comes from.
- name: Genetic counselling
  description: >-
    Recurrence risk for future pregnancies of carrier parents is 25%, and once
    a family's variants are known, carrier and prenatal testing become
    available. Counselling must also address the genetically distinct
    dominant (GFI1B) and X-linked (GATA1) disorders that produce a similar
    smear, since the recurrence risk differs entirely.
  notes: >-
    The 25% recurrence risk is the Mendelian consequence of the autosomal
    recessive inheritance this entry evidences, not a separately measured rate.
    No cited source reports it as an observed frequency, and none needs to.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20709904
    reference_title: 'Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mode of inheritance was autosomal recessive (AR) in 11 and
      indeterminate in 3 families.
    explanation: >-
      The inheritance mode that determines the recurrence risk counselling rests
      on.
animal_models:
- name: Nbeal2 knockout mouse
  species: Mouse
  genotype: Nbeal2-/-
  publication: PMID:23863626
  description: >-
    The principal model, independently generated by more than one group with
    concordant results — including a spontaneous 8 bp Nbeal2 deletion found
    incidentally in an unrelated mutagenesis screen, which reproduces the same
    phenotype and so was not shaped by anyone's expectation of it. It
    reproduces the human syndrome closely —
    splenomegaly, macrothrombocytopenia, absent platelet alpha-granules and
    their cargo — and adds the functional measurements that cannot be made in
    patients: impaired adhesion, aggregation and coagulant activity translating
    into defective arterial thrombus formation, and abnormal megakaryocyte
    maturation, survival and ploidy.
  evidence:
  - reference: PMID:23863626
    reference_title: Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Here we show that Nbeal2-knockout mice display the characteristics of human
      GPS, with defective α-granule biogenesis in MKs and their absence from
      platelets.
    explanation: >-
      The authors' statement of phenotypic correspondence to the human disease,
      which is what licenses using this model for the entry's nodes.
  - reference: PMID:26950939
    reference_title: Spontaneous 8bp Deletion in Nbeal2 Recapitulates the Gray Platelet Syndrome in Mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mice homozygous for the Nbeal2 8 bp deletion (Nbeal2gps/gps) exhibit a
      phenotype similar to human GPS, with significantly reduced platelet counts
      compared to littermate controls (p = 1.63 x 10-7).
    explanation: >-
      An independently arising allele reproducing the phenotype, which is what
      supports the "more than one group, concordant results" claim in the
      description.
  modeled_mechanisms:
  - target: Failure of Alpha-Granule Cargo Packaging
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces the core lesion — defective alpha-granule biogenesis in
      megakaryocytes with absence from platelets and loss of the specific cargo
      proteins depleted in patients.
    limitations: >-
      One documented species difference matters for interpretation: azurophilic
      neutrophil granules are preserved in human GPS but reduced in the mouse,
      so the model overstates the neutrophil granule phenotype. Attributed to the
      review rather than curated as evidence here, since no citable primary
      comparison was established during curation.
    readouts:
    - name: Platelet alpha-granule cargo content (VWF, thrombospondin-1, platelet factor 4)
      target: Failure of Alpha-Granule Cargo Packaging
      direction: DECREASED
      interpretation: >-
        Loss of the same cargo proteins depleted in patient platelets is the
        model's most direct correspondence to the human lesion.
      evidence:
      - reference: PMID:23861251
        reference_title: Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          As in GPS, Nbeal2(-/-) mice exhibit splenomegaly, macrothrombocytopenia,
          and a deficiency of platelet α-granules and their cargo, including von
          Willebrand factor (VWF), thrombospondin-1, and platelet factor 4.
        explanation: >-
          Reports the measurement and direction, with the human comparison stated.
  - target: Leukocyte Granule Deficiency
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces the leukocyte arm — severe reduction in neutrophil granule
      content and dysfunctional NK cells with reduced degranulation — and
      supplies the infection-challenge data that cannot be obtained in patients.
    limitations: >-
      The reduction spans all neutrophil granule subsets in the mouse, whereas
      azurophilic granules are preserved in patients, so the model overstates the
      human neutrophil phenotype. The infection phenotype is also more severe:
      Nbeal2-deficient mice are susceptible to Staphylococcus aureus and murine
      CMV, while patients report mild respiratory infections rather than severe
      ones. NK involvement in human GPS is unestablished, so that half of the
      link is model-only.
    readouts:
    - name: Neutrophil granule content across subsets
      target: Leukocyte Granule Deficiency
      direction: DECREASED
      interpretation: >-
        Granule depletion in a second lineage supports NBEAL2 acting as a general
        granule-biogenesis factor rather than a megakaryocyte-specific one.
      evidence:
      - reference: PMID:28783043
        reference_title: NBEAL2 is required for neutrophil and NK cell function and pathogen defense.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Phenotyping of Nbeal2-deficient neutrophils showed a severe reduction in
          granule contents across all granule subsets.
        explanation: >-
          Reports the measurement and its direction, including the "all subsets"
          scope that diverges from the human phenotype.
    - name: NK cell degranulation
      target: Leukocyte Granule Deficiency
      direction: DECREASED
      interpretation: >-
        Impaired NK degranulation is the second lymphoid readout, and the one
        with no established human counterpart.
      evidence:
      - reference: PMID:28783043
        reference_title: NBEAL2 is required for neutrophil and NK cell function and pathogen defense.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Nbeal2-deficient NK cells were also dysfunctional and showed reduced
          degranulation.
        explanation: >-
          Reports the NK functional deficit measured in the model.
  - target: Macrothrombocytopenia and Impaired Platelet Function
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces both the count/size phenotype and the functional deficit, and
      supplies the in vivo thrombosis readout that establishes the deficit is
      haemostatically consequential rather than only detectable ex vivo.
    limitations: >-
      Murine bleeding assays and laser-induced arterial injury do not map onto
      the clinical bleeding phenotype (epistaxis, menorrhagia, post-procedural
      bleeding) in any quantitative way, so the model cannot be used to predict
      an individual patient's bleeding severity — which is also unpredictable
      from genotype in patients.
    readouts:
    - name: Arterial thrombus formation on intravital imaging
      target: Macrothrombocytopenia and Impaired Platelet Function
      direction: DECREASED
      interpretation: >-
        Defective thrombus formation in vivo confirms the ex vivo platelet
        function deficit has haemostatic consequence.
      evidence:
      - reference: PMID:23863626
        reference_title: Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Nbeal2-deficient platelets displayed impaired adhesion, aggregation, and
          coagulant activity ex vivo that translated into defective arterial
          thrombus formation and protection from thrombo-inflammatory brain
          infarction following focal cerebral ischemia.
        explanation: >-
          Reports the in vivo thrombosis readout and its ex vivo correlates.
differential_diagnoses:
- name: Chediak-Higashi Syndrome
  description: >-
    Caused by loss of LYST, another BEACH-domain vesicle-trafficking protein,
    and likewise a disorder of granule formation - but the affected organelles
    are lysosome-related (dense granules, cytotoxic granules, melanosomes),
    giving immunodeficiency, haemophagocytic lymphohistiocytosis and partial
    albinism with enlarged rather than absent granules. The domain kinship is
    real and is the reason the two are discussed together; the disease is not
    the same.
  evidence:
  - reference: PMID:21765412
    reference_title: "NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Another such protein is CHS1, which is defective in Chediak-Higashi disease (CHD, OMIM #214500), a disorder of immunodeficiency, platelet dense granule defects, partial albinism, and enlarged lysosomes or lysosome-related organelles in hematopoietic cells and melanocytes4,15."
    explanation: >-
      States the shared protein family and the phenotypic differences that
      separate the two disorders.
- name: Dense-Granule Storage Pool Disease and Combined Alpha-Delta SPD
  description: >-
    The storage pool diseases divide by which granule is lost. Isolated
    dense-granule deficiency (including the Hermansky-Pudlak and
    Chediak-Higashi syndromes) and combined alpha-delta deficiency are
    distinguished from this disorder by electron microscopy, not by the
    bleeding pattern.
  evidence:
  - reference: PMID:21765412
    reference_title: "NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bleeding disorders arising from defective platelet granules constitute the platelet storage pool diseases (SPD) and include isolated δ -granule deficiency (delta-SPD), combined α and δ -SPD and isolated α -granule deficiency (GPS; OMIM #139090)3,4,6."
    explanation: >-
      Sets out the storage pool disease classification that positions this
      disorder against its siblings.
- name: ARC Syndrome (VPS33B/VIPAS39)
  description: >-
    Also produces defective alpha-granule biogenesis, but through the
    VPS33B/VPS16B machinery acting earlier in the pathway, and with
    arthrogryposis, renal dysfunction and cholestasis dominating the phenotype.
    The distinction matters mechanistically as well as clinically: it is what
    places NBEAL2's step late in biogenesis.
  evidence:
  - reference: PMID:21781244
    reference_title: Advances in our understanding of the molecular basis of disorders of platelet function.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Defects of α-granule biosynthesis also involve germline VPS33B mutations in the ARC (arthrogryposis, renal dysfunction and cholestasis) syndrome."
    explanation: >-
      Establishes the other genetic route to alpha-granule deficiency and the
      syndromic features that separate it.
- name: GFI1B-related thrombocytopenia
  disease_term:
    preferred_term: platelet-type bleeding disorder 17
    term:
      id: MONDO:0008553
      label: platelet-type bleeding disorder 17
  description: >-
    A dominantly inherited disorder producing enlarged, granule-poor platelets
    that can look like GPS on a smear, but arising through a megakaryocyte
    transcription-factor defect rather than a granule-trafficking one. Curated
    in this repository as MONDO:0008553.
  distinguishing_features:
  - >-
    Autosomal dominant rather than recessive, so the family history and the
    recurrence risk differ completely — the practical reason the distinction
    matters at the point of counselling.
  - >-
    The molecular lesion is in a transcription factor, so the mechanism is not
    the cargo-packaging failure this entry curates.
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The gray platelet syndrome (GPS) (OMIM #139090) is a rare autosomal
      recessive disorder characterized by moderate macrothrombocytopenia, marked
      decrease or absence of platelet alpha (α)-granules, which gives platelets a
      grayish appearance on the blood smear, and mild to moderate bleeding.1
    explanation: >-
      Supports the GPS side of the contrast — autosomal recessive inheritance —
      against which the dominant GFI1B disorder is distinguished. The
      distinguishing features of the GFI1B disorder itself are stated from the
      differential's own MONDO identity rather than from this quote.
- name: GATA1-related X-linked macrothrombocytopenia
  disease_term:
    preferred_term: beta-thalassemia-X-linked thrombocytopenia syndrome
    term:
      id: MONDO:0010745
      label: beta-thalassemia-X-linked thrombocytopenia syndrome
  description: >-
    The GATA1 p.Arg216Gln disorder produces gray, agranular platelets in males
    and was historically called X-linked gray platelet syndrome, but affected
    individuals also have dyserythropoiesis and thalassemia-like red-cell
    changes, and several authors prefer to classify it as X-linked
    thrombocytopenia with thalassemia.
  distinguishing_features:
  - >-
    X-linked inheritance with male predominance, unlike the sex-independent
    recessive inheritance of NBEAL2-related GPS.
  - >-
    Accompanying red-cell abnormalities — dyserythropoiesis and a thalassemia-like
    picture — which have no counterpart in NBEAL2-related GPS.
  evidence:
  - reference: PMID:34408521
    reference_title: 'A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The gray platelet syndrome (GPS) (OMIM #139090) is a rare autosomal
      recessive disorder characterized by moderate macrothrombocytopenia, marked
      decrease or absence of platelet alpha (α)-granules, which gives platelets a
      grayish appearance on the blood smear, and mild to moderate bleeding.1
    explanation: >-
      Supports the GPS side of the contrast — autosomal recessive inheritance —
      against which the X-linked GATA1 disorder is distinguished. The
      dyserythropoietic features of that disorder are stated from its own MONDO
      identity (beta-thalassemia-X-linked thrombocytopenia syndrome) rather than
      from this quote.
discussions:
- discussion_id: gps_nbeal2_molecular_function_unknown
  kind: KNOWLEDGE_GAP
  prompt: >-
    How does loss of NBEAL2 function mechanistically cause defective
    alpha-granule biogenesis?
  attaches_to:
  - pathophysiology#Failure of Alpha-Granule Cargo Packaging
  rationale: >-
    The causal gene has been known since 2011 and the step it acts at has been
    bracketed - late in biogenesis, downstream of VPS33B/VPS16B - but the
    molecular function itself remains unstated. Its predicted interactors,
    WDFY3 and through it LYST, rest entirely on computational prediction, a
    limitation the gene-discovery paper states explicitly. This is a gap in
    molecular mechanism rather than in disease-gene assignment, and it is why
    the cargo-packaging node is necessarily described phenomenologically rather
    than as a pathway.
  proposed_experiments:
  - experiment_id: exp_nbeal2_interactome
    name: Proximity-labelling interactome of NBEAL2 in human megakaryocytes
    description: >-
      Use proximity-dependent biotinylation of tagged NBEAL2 in iPSC-derived
      human megakaryocytes to identify physical interactors at the dense tubular
      system, and test the predicted WDFY3 interaction directly. Replacing
      computationally predicted partners with measured ones is the prerequisite
      for any mechanistic model of the packaging step.
  evidence:
  - reference: PMID:21765412
    reference_title: "NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "How absence of NBEAL2 function in megakaryocytes results in defective α-granule biogenesis remains unknown."
    explanation: >-
      The source's own statement of the gap.
  - reference: PMID:21765412
    reference_title: "NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "These protein-protein interactions are entirely based on computational predictions; future experiments will determine their accuracy."
    explanation: >-
      Supports the caveat that the proposed interactome is unmeasured, which is
      what the proposed experiment addresses. COMPUTATIONAL because the
      interactome being described is network inference without wet-lab
      confirmation - which is the entire point of the item, so any other
      evidence_source would contradict the claim it exists to make.
- discussion_id: gps_myelofibrosis_mechanism_unproven
  kind: KNOWLEDGE_GAP
  prompt: >-
    Is marrow fibrosis in GPS actually caused by constitutive megakaryocyte
    release of fibrogenic cargo, or is that inference from the packaging defect?
  attaches_to:
  - pathophysiology#Progressive Myelofibrosis
  rationale: >-
    The leakage model is the consensus account and it is mechanistically
    natural, but the primary literature states plainly that the basis of the
    myelofibrosis remains unknown, and the fibrogenic-growth-factor step has not
    been demonstrated by direct marrow measurement in patients. The causal edge
    into this node is therefore recorded as having unknown intermediates. What
    would settle it is quantification of PDGF and TGF-beta in GPS marrow
    alongside fibrosis grade, or a fibrosis rescue in the knockout by blocking
    those factors.

    Two further points bear on why this has stayed open. First, a second,
    non-exclusive candidate exists and is rarely stated alongside the leakage
    model: microarray data in GPS fibroblasts showed overexpression of
    fibronectin, which is essential for proplatelet formation and critical for
    megakaryocyte-matrix interaction - a matrix mechanism rather than a
    cargo-release one. The two predict different things about whether
    suppressing megakaryocyte output would slow the fibrosis. Second, the
    obstacle is concrete rather than merely one of priority: the fibrotic marrow
    itself prevented the gene-discovery authors from harvesting enough
    megakaryocytes to culture, and megakaryocytes are the only cell type that
    expresses the packaging defect. That is why the mouse, which reproduces the
    splenomegaly and granule phenotype, is the natural system in which to test a
    hypothesis human tissue has resisted.
  evidence:
  - reference: PMID:21765412
    reference_title: "NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our previous microarray data in GPS fibroblasts showed overexpression of fibronectin11, essential for proplatelet formation in cultured megakaryocytes12 and critical for megakaryocyte-matrix interactions13."
    explanation: >-
      Supports the second, matrix-based candidate mechanism named in this gap,
      which the consensus leakage model does not subsume. IN_VITRO because the
      measurement is a microarray on cultured patient fibroblasts, not an
      observation in patients.
  - reference: PMID:21765412
    reference_title: "NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The fibrotic nature of the GPS bone marrow prevented us from obtaining sufficient bone marrow for ex-vivo expansion of GPS megakaryocytes, the only cell type that expresses the GPS phenotype of defective α-granule biogenesis."
    explanation: >-
      Documents the specific methodological obstacle that has kept this gap
      open, and why a model system rather than patient tissue is the tractable
      route.
- discussion_id: gps_ctla4_therapeutic_hypothesis
  kind: EMERGING_HYPOTHESIS
  prompt: >-
    Should CTLA-4-Ig be trialled for autoimmune complications of GPS, and in
    which patients?
  attaches_to:
  - pathophysiology#Reduced Effector T Cell CTLA-4 Expression
  rationale: >-
    The mechanistic case is unusually clean for an ultra-rare disease: NBEAL2
    binds CTLA-4, its loss lowers CTLA-4 on effector but not regulatory T cells,
    knockdown reproduces this in healthy T cells, and the closely related LRBA
    deficiency responds to CTLA-4-Ig. But no GPS patient has been reported
    treated this way, autoimmunity affects only a subset, and it is unknown
    whether CTLA-4 expression predicts who develops it. This is recorded as an
    emerging hypothesis with a licensed drug attached, not as a treatment.
- discussion_id: gps_mouse_neutrophil_granule_mismatch
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Does the Nbeal2 knockout mouse model the human neutrophil phenotype, given
    that azurophilic granules are preserved in patients but reduced in the
    mouse?
  attaches_to:
  - animal_models#Nbeal2 knockout mouse
  rationale: >-
    The mouse reproduces the platelet lesion with high fidelity, which is why it
    carries the entry's model links. Its neutrophil phenotype is a different
    matter: azurophilic granules are described as preserved in human GPS but
    reduced in the knockout. Evidence therefore exists on both sides and
    disagrees, which makes this a translational-validity question rather than a
    gap — and it matters, because the innate-immune arm of GPS is exactly the
    part that the mouse is currently being used to study.
notes: >-
  Scope. This entry curates NBEAL2-related autosomal recessive gray platelet
  syndrome. The dominantly inherited GFI1B disorder and the X-linked GATA1
  p.Arg216Gln disorder produce a similar blood smear and are sometimes named as
  GPS variants; both are curated here as differential diagnoses rather than as
  subtypes, since their mechanisms and recurrence risks differ entirely. The
  deep-research preflight flagged GATA1 and GFI1B as rival genes in the report
  for this reason; those sections were excluded from the mechanism curation.

  Deliberate omissions, corrected. An earlier revision listed several
  quantitative claims as uncurated for want of a citable source. That was partly
  a misreading of this PR's own cache: `references_cache/PMID_34408521.md` is
  stored as full text, not as an abstract, and its Management section and body
  contain quotable statements of most of those claims. Now curated from it: the
  58% myelofibrosis rate at a median age of 28.5 years, the "around half" figure
  for autoimmunity/autoantibodies, the 17% infection-susceptibility figure, the
  median platelet count of 57 x 10^9/L, the splenectomy result, haematopoietic
  stem cell transplantation, the antifibrinolytic/NSAID-avoidance measures, and
  the thrombopoietin-receptor-agonist caution. Read a cached reference's
  `content_type` before deciding what it can support.

  What remains uncurated: the report's own reference validation flagged four
  quotes as unsupported, and none of those quoted strings is used anywhere in
  this entry. The zebrafish morpholino tail-bleeding percentage and the
  proinflammatory-megakaryocyte/metastasis-resistance mouse work still have no
  citable cached source and are not curated; the desmopressin management point
  likewise rests only on non-citable sources, so it is absent while the
  haemostatic measures that the review does state are curated.

📚

References & Deep Research

References

2

PMID:32693407

Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.

No top-level findings curated for this source.

PMID:34408521

A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Gray Platelet Syndrome (GPS): Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 30 citations 2026-08-25T04:38:57.426795

Gray Platelet Syndrome (GPS): Comprehensive Research Report

1. Disease Information

Overview. Gray platelet syndrome (GPS) is a rare inherited bleeding disorder classically defined by the triad of macrothrombocytopenia (low platelet count with enlarged platelets), selective deficiency or absence of platelet α-granules (the organelles that package von Willebrand factor, platelet factor 4, PDGF, thrombospondin-1, fibrinogen and other secreted proteins), and a pale, gray appearance of platelets on Wright-stained peripheral blood smear — the finding that gives the syndrome its name, reflecting the loss of the granule content that normally stains purple/azurophilic. The disorder was first described by Raccuglia in 1971. Long-term complications include progressive bone marrow (myelo)fibrosis and splenomegaly (ScienceDirect overview; OMIM #139090).

Key identifiers: - OMIM: #139090 (Gray Platelet Syndrome, phenotype entry); causal gene NBEAL2 is OMIM 614169 - Gene: NBEAL2 (Neurobeachin-Like 2), chromosome 3p21 - Orphanet: ORPHA:721 (the search surfaced Orphanet's expert page at Expert=721 rather than an ORPHA:317 code) - UMLS/GTR concept: C0272302 - Additional causal genes for GPS-like phenotypes: GFI1B (autosomal dominant GPS) and GATA1 (X-linked macrothrombocytopenia with α-granule deficiency, historically also called "X-linked gray platelet syndrome," though some authors argue it is better termed "X-linked thrombocytopenia with thalassemia" (XLTT) because of accompanying dyserythropoiesis) (ashpublications.org/blood/article/109/8/3297; pubmed.ncbi.nlm.nih.gov/17881640/). - Synonyms:* GPS; platelet alpha-granule deficiency; α-storage pool deficiency (α-SPD, when referring to the biochemical defect broadly).

Evidence basis: Most published data derive from aggregated case series and international patient-cohort natural-history studies (e.g., a 116-individual, 25-patient/14-family cohort by Gunay-Aygun et al., and a larger international registry underlying Sims et al. 2020), supplemented by individual case reports and reference to model organisms (mouse, zebrafish) — not large-scale EHR/claims data, given the disease's extreme rarity.

Sources: - Entry - #139090 - GRAY PLATELET SYNDROME; GPS (OMIM) - Gray Platelet Syndrome - an overview | ScienceDirect Topics - Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p | Blood - X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation | Blood - Why the disorder induced by GATA1 Arg216Gln mutation should be called "X-linked thrombocytopenia with thalassemia"

2. Etiology

2.1 Disease causal factors — genetic, and heterogeneous

GPS is genetically heterogeneous:

Autosomal recessive GPS (the majority, "classic" GPS): biallelic (homozygous or compound heterozygous) loss-of-function mutations in NBEAL2 (3p21). NBEAL2 encodes a 2,754-amino-acid multidomain scaffolding protein (BEACH, PH, and WD40 domains) related to LYST (the lysosomal trafficking regulator mutated in Chediak-Higashi syndrome). Most GPS-causing NBEAL2 variants are nonsense or frameshift, producing premature truncation; splice-site variants are also reported. NBEAL2 has 54 exons — one of the larger genes implicated in an inherited platelet disorder (OMIM #139090; Nature Genetics ng.883/ng.885/ng.887 papers, 2011).
Autosomal dominant GPS: a dominant-negative nonsense mutation in GFI1B (growth factor independent 1B transcription factor), reported by Monteferrario et al., NEJM 2014 (PMID not directly retrieved, DOI 10.1056/NEJMoa1308130), causing GPS-like macrothrombocytopenia with α-granule deficiency through a distinct megakaryocyte-transcription-factor mechanism rather than a granule-trafficking defect per se.
X-linked GPS-like phenotype: the GATA1 p.Arg216Gln mutation, reported in a family with sex-linked macrothrombocytopenia and gray, agranular platelets; because affected males also show dyserythropoiesis and mild thalassemia-like red cell changes, some authors reclassify this entity as XLTT rather than true GPS (ashpublications.org/blood/article/109/8/3297; pubmed.ncbi.nlm.nih.gov/17881640/).
Molecular mechanism (NBEAL2-GPS): NBEAL2 is required for α-granule biogenesis in megakaryocytes and platelets. Loss of NBEAL2 causes "a defect in the transfer of protein cargo into the lumen of developing α-granules or in the retention of granule content" (PMID: 34408521), leaving rudimentary α-granule precursors and premature/ectopic release of granule cargo within the bone marrow, which is now understood to drive downstream complications (see Mechanism section).

2.2 Risk factors

Genetic: biallelic pathogenic NBEAL2 variants (necessary and sufficient for recessive GPS); a single dominant-negative GFI1B allele; hemizygous GATA1 p.Arg216Gln in males. Consanguinity raises risk of biallelic NBEAL2 inheritance given the extreme rarity of any single pathogenic allele. No modifier genes or genotype–phenotype correlation have been established — "No established genotype-phenotype correlation" despite 86 different NBEAL2 variants identified across 69 pedigrees, 65% homozygous and 35% compound heterozygous (PMID 34408521 / Deep Dive review).
Environmental/lifestyle: none specifically established as disease-causing (GPS is purely Mendelian); however, environmental triggers such as surgery, dental work, and trauma precipitate bleeding episodes in affected individuals rather than causing the underlying disease.
Population-specific founder variants: not systematically documented in the literature surveyed; GPS has been reported across diverse populations (European, Middle Eastern, Japanese, and others) without a single dominant founder allele.

2.3 Protective factors

No genetic or environmental protective factors against GPS itself are described in the literature (the condition is monogenic and fully penetrant when biallelic loss-of-function NBEAL2 variants are present). This is expected given its rarity and recessive/dominant-negative single-gene basis rather than complex/polygenic risk architecture.

2.4 Gene–environment interactions

None specifically documented for GPS causation. However, environmental/procedural exposures (surgery, childbirth, anticoagulant/antiplatelet drug use, NSAIDs) interact with the underlying platelet defect to precipitate clinically significant bleeding — this is a gene–environment interaction affecting manifestation severity, not disease occurrence.

Sources: - NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules | Nature Genetics - Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome - PubMed (21765411) - A Dominant-Negative GFI1B Mutation in the Gray Platelet Syndrome | NEJM - A Deep Dive into the Pathology of Gray Platelet Syndrome (PMID 34408521)

3. Phenotypes

3.1 Hematologic/bleeding phenotypes

Macrothrombocytopenia — enlarged (though not "giant") platelets, low count. Median platelet count in the largest reported cohort (47 patients) was 57 × 10⁹/L (range 28–105) (PMID 34408521). Suggested HPO: Thrombocytopenia (HP:0001873), Abnormal platelet morphology / Giant platelets concept.
Bleeding tendency, variable severity. In the Gunay-Aygun 2010 cohort of 19 evaluable patients: 37% mild, 21% moderate, 42% severe bleeding (ashpublications.org/blood/article/116/23/4990). Manifestations include easy bruising (ecchymoses), epistaxis, prolonged post-surgical/post-dental bleeding, menometrorrhagia, and (uncommonly) intracranial hemorrhage.
Onset: typically infancy or early childhood, though presentation can extend into adolescence/adulthood in milder cases; one recent case report describes neonatal presentation with VACTERL association (PMC10699155).

3.2 Bone marrow / hematologic progression phenotypes

Myelofibrosis: a hallmark long-term complication. In the largest immune-dysregulation cohort, 58% of patients developed myelofibrosis at a median age of 28.5 years (range 10–52); in an earlier subset, 57% (13/23) of biopsied patients showed marrow fibrosis (10–52 years of age) (PMID 34408521; medrxiv/Sims 2020 Blood paper). Fibrosis is generally stable rather than rapidly progressive, though it can eventually cause marrow failure.
Splenomegaly: common, thought to reflect compensatory extramedullary hematopoiesis as marrow fibrosis impairs normal hematopoiesis; occasionally severe enough to prompt splenectomy consideration (though splenectomy does not correct platelet counts and is not generally recommended — see Treatment).
Emperipolesis: megakaryocyte emperipolesis of neutrophils is a recognized bone marrow histologic feature.
Pancytopenia: can occur in advanced disease with significant marrow fibrosis (academic.oup.com/ajcp/article/156/2/253).

3.3 Laboratory abnormalities

Elevated serum vitamin B12: "Raised serum vitamin B12 levels are an almost universal finding in GPS patients" (PMID 34408521), with most patients showing levels ≥50% above the local upper reference limit; mechanism not fully elucidated but may relate to increased transcobalamin release or turnover.
Reduced leukocyte counts and decreased neutrophil granulation are recognized, along with impaired neutrophil extracellular trap (NET) formation.
Elevated acute-phase reactants: liver-derived CRP and lipopolysaccharide-binding protein elevated in patient plasma, indicating systemic low-grade inflammation (PMID 34408521).

3.4 Immune/autoimmune phenotypes (novel, increasingly recognized)

From the international cohort study by Sims et al. (Blood 2020) and the CTLA-4 mechanistic follow-up (Nat Commun 2023): - 26% of GPS patients carry a diagnosed autoimmune disease (Hashimoto's thyroiditis, rheumatoid arthritis, alopecia, discoid lupus erythematosus, vitiligo). - 59% test positive for autoantibodies (rheumatoid factor, perinuclear ANCA, ANA). - 17% report increased infection susceptibility, particularly mild upper respiratory infections and otitis media; severe infections are uncommon. - GPS "can mimic autoimmune lymphoproliferative syndrome" in some presentations (sciencedirect.com/science/article/pii/S0006497120308296). - Mechanistically, NBEAL2 deficiency causes low CTLA-4 expression in activated conventional (effector) T cells (regulatory T cells are relatively spared), providing biological rationale for CTLA-4-Ig (e.g., abatacept) as a therapeutic consideration in GPS patients with autoimmune complications (Nature Communications 2023, PMC10287742).

3.5 Frequency/severity/progression summary

Symptom onset: predominantly childhood.
Severity: variable, mild to severe, with no strong genotype–phenotype correlation.
Progression: stable macrothrombocytopenia/bleeding tendency from birth, with progressive myelofibrosis and splenomegaly developing over years to decades (median myelofibrosis onset ~28.5 years).
Quality of life: chronic bleeding risk affects activities involving trauma risk, surgery planning, and dental care; fatigue/anemia can occur with pancytopenia in advanced marrow fibrosis. No disease-specific QOL instrument was identified in the search; general bleeding-disorder QOL tools (e.g., used in von Willebrand disease or ITP) are typically adapted.

Sources: - Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome | Blood - A Deep Dive into the Pathology of Gray Platelet Syndrome (PMC8364843) - NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells | Nature Communications - Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome - Gray Platelet Syndrome Presenting With Pancytopenia, Splenomegaly, and Bone Marrow Fibrosis - Gray Platelet Syndrome in a Neonate With VACTERL Association (PMC10699155)

4. Genetic/Molecular Information

4.1 Causal genes

Gene	HGNC/locus	Inheritance	Mechanism
NBEAL2	3p21; OMIM *614169	Autosomal recessive (biallelic LoF)	Loss of scaffolding protein required for α-granule cargo retention/biogenesis
GFI1B	9q34.13	Autosomal dominant	Dominant-negative nonsense mutation in a megakaryocyte transcription factor (Monteferrario et al., NEJM 2014)
GATA1	Xp11.23	X-linked	p.Arg216Gln — hemizygous missense in a hematopoietic transcription factor; overlapping GPS-like macrothrombocytopenia plus dyserythropoiesis/thalassemia features (debated nosology: XLTT vs. "X-linked GPS")

4.2 Discovery history

NBEAL2 was independently identified as the GPS gene by three simultaneous 2011 Nature Genetics papers: 1. Gunay-Aygun et al., "Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome," Nat Genet 2011;43:735–737 (PMID 21765411). 2. Albers et al., "NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules," Nat Genet 2011;43:732–734. 3. Kahr et al., "Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome," Nat Genet 2011;43:738–740.

This followed prior linkage mapping of an autosomal-recessive GPS locus to a 9.4-Mb interval at 3p21.1–3p22.1 (containing 197 protein-coding genes) by Gunay-Aygun et al. (Blood 2010;116(23):4990–5001).

4.3 Variant spectrum and classification

Most pathogenic NBEAL2 variants are nonsense mutations generating premature stop codons; frameshift and splice-site variants are also common.
86 different NBEAL2 variants have been identified across 69 pedigrees; 65% of patients are homozygous, 35% compound heterozygous (PMID 34408521).
No robust genotype–phenotype correlation has been established for bleeding severity, myelofibrosis onset, or immune complications.
ClinVar/VarSome-style classification (pathogenic/likely pathogenic per ACMG/AMP) would typically apply loss-of-function criteria (PVS1) given the truncating nature of most variants; individual variant curation should be done via ClinVar for KB curation purposes.
Population frequency: given <1/1,000,000 prevalence and reported cases numbering only ~60–100 worldwide, individual pathogenic NBEAL2 alleles are extremely rare in population databases (one reported variant carried a minor allele frequency of ~7.2 × 10⁻⁶, i.e., ultra-rare in gnomAD-scale data).
A recent case report highlights that not all NBEAL2 variants produce classic GPS — "NBEAL2 gene mutations do not always lead to gray platelet syndrome" (PMC11460870), underscoring variable expressivity/incomplete correlation between genotype and the full clinical syndrome.

4.4 Protein domain structure

NBEAL2 encodes a 2,754-amino-acid protein containing PH (pleckstrin homology) and BEACH (beige and Chediak-Higashi) domains plus WD40 repeats, structurally related to LYST (lysosomal trafficking regulator, mutated in Chediak-Higashi syndrome) — placing GPS within a family of "BEACH-domain protein" vesicular-trafficking disorders.

4.5 Molecular interactions

NBEAL2 physically interacts with CTLA-4 (co-immunoprecipitation confirmed), and its loss reduces CTLA-4 surface expression specifically in activated conventional (non-regulatory) T cells (Nat Commun 2023), linking the platelet-granule trafficking machinery to a T-cell immune checkpoint mechanism and explaining, at least in part, the autoimmune phenotype seen in some GPS patients.

4.6 Chromosomal abnormalities

No recurrent large chromosomal rearrangements (aneuploidy/translocation) are described as causal for GPS; it is a single-gene (point mutation/indel) disorder in the great majority of cases.

Sources: - NBEAL2 is mutated in gray platelet syndrome... | Nature Genetics - Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome - PubMed - Entry - *614169 - NEUROBEACHIN-LIKE 2; NBEAL2 - OMIM - Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p | Blood - NBEAL2 deficiency in humans leads to low CTLA-4 expression | Nature Communications - NBEAL2 gene mutations do not always lead to gray platelet syndrome: A case report (PMC11460870) - A Deep Dive into the Pathology of Gray Platelet Syndrome (PMC8364843, PMID 34408521)

5. Environmental Information

GPS is a monogenic disorder with no established environmental, lifestyle, or infectious causal factors. Environmental relevance is limited to: - Trigger/exacerbating exposures for bleeding events: surgery, dental extraction, trauma, childbirth, anticoagulant/antiplatelet medication exposure. - Infectious agents: not causal, but GPS patients (particularly via impaired neutrophil NET formation and NK-cell dysfunction) show increased susceptibility to infections, notably mild upper respiratory infections and otitis media in ~17% of an international cohort (PMID 34408521); mouse model data additionally show increased susceptibility to CMV infection related to NK-cell degranulation defects (see Mechanism, §6.5).

No CTD/TOXNET/EPA-indexed toxin, occupational exposure, or dietary factor was identified as contributing to GPS risk or severity in the literature surveyed.

6. Mechanism / Pathophysiology

6.1 Core defect: impaired α-granule biogenesis

NBEAL2 acts as a scaffolding protein required during megakaryocyte maturation for the biogenesis of platelet α-granules. In its absence, "α-granules" in megakaryocytes and platelets remain as rudimentary precursors rather than maturing normally — cargo proteins (von Willebrand factor, platelet factor 4, thrombospondin-1, fibrinogen, PDGF, TGF-β, and others) fail to be properly packaged, trafficked into the granule lumen, or retained. The leading model is that "NBEAL2 deficiency leads to a defect in the transfer of protein cargo into the lumen of developing α-granules or in the retention of granule content" (PMID 34408521).

6.2 Downstream consequence: megakaryocyte cargo leakage and marrow fibrosis

Because megakaryocytes still synthesize α-granule cargo proteins but cannot properly compartmentalize them, these proteins — including fibrogenic growth factors (PDGF, TGF-β) — are believed to leak directly into the bone marrow microenvironment from immature, defective megakaryocytes. Chronic exposure of marrow stroma to these fibroblast-activating factors is the proposed mechanism for progressive myelofibrosis, a hallmark long-term complication. Proinflammatory cytokine secretion from abnormal megakaryocytes is a related contributing mechanism (PMID 34408521). Mouse-model work (ScienceDirect, "proinflammatory megakaryocytes and α-granule loss cause myelofibrosis") extends this: Nbeal2−/− megakaryocytes are intrinsically proinflammatory, and this proinflammatory megakaryopoiesis, together with loss of α-granules, drives fibrosis — and, intriguingly, this same biology confers metastasis resistance in the mouse model, an unexpected link between platelet granule content and tumor microenvironment biology.

6.3 Platelet-level consequences

Platelets are enlarged with a gray, agranular appearance on light microscopy due to loss of the normally purple-staining α-granule content.
Dense granules and other organelles remain relatively intact, distinguishing GPS from combined-storage-pool disorders.
Ultrastructurally, platelets show prominent cytoplasmic vacuolization.
P-selectin (normally stored in α-granules and translocated during activation) is present at relatively normal levels in Nbeal2−/− platelets despite the granule defect, and VPS33B/VPS16B levels are normal — this indicates NBEAL2 acts downstream/independent of the VPS33B–VPS16B trafficking axis (also implicated in the related disorder ARC syndrome/α-granule deficiency).

6.4 Innate immune / neutrophil involvement

Beyond platelets, NBEAL2 is required for normal neutrophil granule content and function: patients show reduced specific and gelatinase granule content, elevated circulating neutrophil granule proteins (suggesting inappropriate degranulation), and impaired neutrophil extracellular trap (NET) formation in response to PMA and Candida albicans stimulation, seen in 59% of one patient cohort (PMID 34408521). This connects GPS mechanistically to innate immune/pathogen-defense pathways, consistent with the title finding of an earlier mechanistic paper, "NBEAL2 is required for neutrophil and NK cell function and pathogen defense" (PMC5669559).

6.5 NK cell and adaptive immune involvement

Mouse-model and human data show NK cell dysfunction — reduced NK cell numbers, impaired degranulation, altered LAMP-1 trafficking upon stimulation, and increased susceptibility to CMV infection in Nbeal2-deficient mice. On the adaptive side, NBEAL2 interacts directly with CTLA-4, and its loss selectively reduces CTLA-4 surface expression on activated conventional (effector) T cells, while regulatory T cells are relatively unaffected — a mechanistic explanation for the elevated rate of autoimmune disease and autoantibody positivity observed clinically, and the rationale for exploring CTLA-4-Ig (abatacept)-based immunomodulation in GPS patients with autoimmune manifestations (Nat Commun 2023).

6.6 Causal chain summary (upstream → downstream)

Molecular/genetic trigger: biallelic NBEAL2 loss-of-function (or dominant-negative GFI1B, or GATA1 p.Arg216Gln) → [GO:0140252 storage vesicle biogenesis]-type defect
Cellular: defective α-granule cargo packaging/retention in megakaryocytes and platelets → rudimentary granule precursors; concurrent defects in neutrophil specific/gelatinase granules and NK-cell lytic granule trafficking
Tissue: cargo/cytokine leakage from megakaryocytes into bone marrow stroma → fibroblast activation → myelofibrosis; compensatory extramedullary hematopoiesis → splenomegaly
Organism-level: macrothrombocytopenia and impaired platelet secretory function → bleeding diathesis; impaired neutrophil/NK function → infection susceptibility; dysregulated T-cell CTLA-4 expression → autoimmunity

Suggested GO terms: GO:0032469 endoplasmic reticulum calcium ion homeostasis (not directly relevant — omit); more precisely, GO:0060155 platelet dense granule organization (dense granule, contrast case), and for α-granules the relevant (if less standard) term concept is platelet alpha-granule organization. Suggested CL terms: CL:0000556 megakaryocyte, CL:0000233 platelet, CL:0000775 neutrophil, CL:0000623 natural killer cell, CL:0000910 effector T cell.

Sources: - A Deep Dive into the Pathology of Gray Platelet Syndrome (PMC8364843) - Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice - ScienceDirect - Abnormal megakaryocyte development and platelet function in Nbeal2−/− mice | Blood - Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice - PubMed / JCI - NBEAL2 is required for neutrophil and NK cell function and pathogen defense (PMC5669559) - NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells | Nature Communications

7. Anatomical Structures Affected

Organ level (primary): bone marrow (megakaryopoiesis, fibrosis), spleen (splenomegaly, extramedullary hematopoiesis), circulating blood (platelets, neutrophils, NK cells, T cells).
Organ level (secondary/complication): liver (elevated acute-phase reactants suggest hepatic involvement in the systemic inflammatory response, though not primary organ damage); potential hepatomegaly reported in at least one pediatric case alongside immune dysregulation (PMC12540000, "Unveiling the Gray: A Rare Case of Gray Platelet Syndrome With Hepatomegaly and Immune Dysregulation in a 14-Year-Old").
Body systems: hematologic/hematopoietic system (primary); immune system (secondary, increasingly recognized); in GATA1-related X-linked disease, additionally the erythroid lineage (dyserythropoiesis, mild thalassemia-like phenotype).
Tissue/cell level: megakaryocytes and platelets (α-granule loss); neutrophils (specific/gelatinase granule reduction); NK cells (lytic granule/degranulation defects); conventional (effector) T cells (reduced CTLA-4 surface expression). Suggested CL terms as above.
Subcellular level: the platelet α-granule (a secretory/storage granule) is the primary defective organelle — GO Cellular Component concept "platelet alpha granule" (GO:0031091); more broadly, membrane-bound secretory granule biogenesis pathways (BEACH-domain-protein-dependent vesicular trafficking, shared with lysosome-related organelle biogenesis pathways as in Chediak-Higashi syndrome/LYST).
Localization: systemic/hematologic — no strict lateralization; splenomegaly and marrow fibrosis are generalized rather than focal.

Sources: - Unveiling the Gray: A Rare Case of Gray Platelet Syndrome With Hepatomegaly and Immune Dysregulation in a 14-Year-Old (PMC12540000) - A Deep Dive into the Pathology of Gray Platelet Syndrome (PMC8364843)

8. Temporal Development

Onset: typically infancy to early childhood; some patients present in adolescence with milder bleeding; rare neonatal presentations reported (e.g., in the context of VACTERL association, PMC10699155). Onset pattern is generally insidious for the bleeding tendency (present from birth/early life) but the marrow/spleen complications emerge later.
Progression: the core platelet defect and bleeding tendency are present from birth and relatively stable; myelofibrosis and splenomegaly are progressive, age-related complications, with myelofibrosis documented from age 10 up to 52 years (median onset ~28.5 years) in cohort data (PMID 34408521). This represents a biphasic natural history: an early, stable bleeding-disorder phase followed by a later, progressive myeloproliferative/fibrotic phase.
Disease course pattern: chronic and lifelong; not relapsing-remitting in the classic sense, though bleeding episodes are episodic/trauma-triggered against a background of chronic thrombocytopenia.
Critical periods: early childhood diagnosis is important for anticipatory bleeding-risk management (surgery/dental planning); ongoing surveillance (CBC, marrow assessment, spleen size) is warranted through adulthood given the delayed-onset fibrotic complications.
Remission: no spontaneous remission described; the disorder is a fixed genetic lesion with a progressive downstream phenotype.

Sources: - Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome | Blood - A Deep Dive into the Pathology of Gray Platelet Syndrome (PMC8364843)

9. Inheritance and Population

9.1 Epidemiology

Prevalence: extremely rare — fewer than 1 in 1,000,000 individuals; approximately 60 cases described in the literature historically (with more recent cohort/registry work bringing total reported patients, e.g., in the 47–116-individual cohorts cited above, into the low hundreds worldwide when aggregated across studies). Affects males and females roughly equally for the autosomal forms.
No incidence (new-cases-per-year) figures were identified; given the rarity, most epidemiological framing is prevalence/case-count based (Orphanet-style rare-disease reporting) rather than incidence-rate based.

9.2 Inheritance patterns

Predominant pattern: autosomal recessive (biallelic NBEAL2 variants) — the classic and most common form.
Autosomal dominant form: dominant-negative GFI1B nonsense mutation (NEJM 2014).
X-linked form: hemizygous GATA1 p.Arg216Gln in males (debated whether "true" GPS or a related but distinct entity, XLTT).
GPS is thus explicitly recognized as a genetically heterogeneous disorder with more than one molecular cause and more than one inheritance pattern — a key nosological point (Orphanet/GTR summaries; OMIM #139090).
Penetrance: biallelic NBEAL2 loss-of-function appears highly (if not fully) penetrant for the core macrothrombocytopenia/α-granule-deficiency phenotype, though a recent case report notes that "NBEAL2 gene mutations do not always lead to gray platelet syndrome" (PMC11460870), suggesting some variability.
Expressivity: clearly variable — bleeding severity spans mild to severe with no genotype-phenotype correlation; timing of myelofibrosis onset and presence/absence of autoimmune complications also vary substantially between patients.
Consanguinity: plausibly elevates risk of autosomal recessive GPS given the extreme rarity of individual pathogenic alleles, consistent with general principles for ultra-rare AR disorders, though a specific consanguinity-rate statistic was not retrieved in this search.
Carrier frequency: not established in gnomAD-scale population data given the rarity and allelic heterogeneity of NBEAL2 pathogenic variants (individual variants reported at MAF ~7×10⁻⁶).

9.3 Population demographics

Reported across diverse populations (European, North American, Middle Eastern, and Asian cohorts appear in the literature), without strong evidence for a specific founder population or geographic clustering identified in this search.
Sex ratio: approximately equal for autosomal forms; male-restricted for the X-linked GATA1 form (with potential milder/variable expression in female carriers, as typical for X-linked conditions, though not specifically detailed here).

Sources: - Gray platelet syndrome - NIH Genetic Testing Registry (GTR) - NCBI - Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p | Blood - gray platelet syndrome - National Organization for Rare Disorders - NBEAL2 gene mutations do not always lead to gray platelet syndrome: A case report (PMC11460870)

10. Diagnostics

10.1 Clinical/laboratory tests

Peripheral blood smear (Wright stain): the defining diagnostic clue — large, pale/gray, agranular platelets on light microscopy.
CBC: thrombocytopenia with enlarged mean platelet volume; may show leukopenia; pancytopenia in advanced marrow fibrosis.
Platelet aggregometry: light transmission aggregometry used as part of extended functional work-up.
Granule-release/secretion assays: used to demonstrate α-granule cargo deficiency (e.g., reduced releasable PF4, VWF, thrombospondin-1).
Transmission electron microscopy (TEM): gold-standard structural confirmation of absent/rudimentary α-granules with preserved dense granules; recommended as extended testing in the diagnostic algorithm (researchgate.net/publication/376884293).
Serum vitamin B12: characteristically elevated (near-universal finding) — a useful ancillary biochemical clue.
Bone marrow biopsy: assesses for myelofibrosis, megakaryocyte morphology/emperipolesis; used at diagnosis and for longitudinal monitoring given progressive fibrosis risk.
Imaging: abdominal ultrasound/CT/MRI to assess splenomegaly.

10.2 Genetic testing

First-line approach: targeted NBEAL2 sequencing or a multi-gene inherited-thrombocytopenia/platelet-disorder panel (including GFI1B, GATA1, and other macrothrombocytopenia genes such as MYH9, ANKRD26, ITGA2B/ITGB3, etc., for differential diagnosis) is the recommended diagnostic approach given clinical/smear suspicion of GPS.
Whole exome sequencing (WES): historically instrumental in identifying NBEAL2 itself (Gunay-Aygun et al. 2011 used exome sequencing of the 3p21 linkage interval); remains useful when panel testing is non-diagnostic or the phenotype is atypical.
Whole genome sequencing (WGS): useful for detecting deep intronic/splice variants or structural variants missed by exome/panel approaches, though not specifically documented as routine for GPS in this search.
Chromosomal microarray/karyotyping/FISH: not primary diagnostic modalities for GPS (a single-gene, largely point-mutation/indel disorder), though may be used to exclude large deletions or in cases with additional syndromic features (e.g., the VACTERL-association case report).

10.3 Clinical criteria and differential diagnosis

No formal consensus diagnostic scoring system (akin to DSM/ICD criteria) was identified; diagnosis rests on the combination of clinical bleeding history, characteristic blood-smear findings, granule-content/functional testing, and confirmatory genetic testing.

Key differential diagnosis (inherited platelet disorders with granule/size abnormalities): - GFI1B-related thrombocytopenia: reduced/absent granules, enlarged platelets (overlaps with classic GPS phenotype but autosomal dominant). - ANKRD26-related thrombocytopenia: reduced granules but normal-sized platelets (key distinguishing feature from GPS). - GATA1-related X-linked macrothrombocytopenia/XLTT: GPS-like platelets plus dyserythropoiesis/thalassemia features. - ARC syndrome (VPS33B/VPS16B): overlapping α-granule biogenesis defect but with additional arthrogryposis, renal dysfunction, and cholestasis. - Other inherited macrothrombocytopenias (MYH9-related disorders, Bernard-Soulier syndrome) are distinguished by platelet glycoprotein expression and additional syndromic features. - Acquired gray-platelet-like phenotype: case reports describe an "acquired gray platelet syndrome" in the context of JAK2-positive post-polycythemia vera myelofibrosis — important to distinguish acquired myeloproliferative-neoplasm-associated granule loss from the inherited disorder (link.springer.com/article/10.1007/s00277-025-06587-5).

10.4 Screening

No population-based newborn or carrier screening program specific to GPS was identified, consistent with its extreme rarity; diagnosis is case-finding based on clinical bleeding presentation and abnormal platelet morphology.

Sources: - Gray Platelet Syndrome: Diagnosis and Management (Springer Nature Link chapter) - A Deep Dive into the Pathology of Gray Platelet Syndrome (PMC8364843) - Acquired Gray platelet syndrome as a rare hematologic complication in a case of JAK2-positive post polycythemia Vera myelofibrosis - Gray Platelet Syndrome in a Neonate With VACTERL Association (PMC10699155)

11. Outcome/Prognosis

Overall prognosis: GPS is generally considered a chronic, non-fatal bleeding disorder for most patients — "the bleeding tendency in this syndrome generally varies from mild to moderate, and no specific treatment is usually needed" for many patients, though a substantial minority (42% severe bleeding in one cohort) have significant hemorrhagic morbidity, including rare intracranial hemorrhage.
Long-term morbidity drivers: progressive myelofibrosis (58% by variable ages, median onset ~28.5 years) and splenomegaly are the major sources of long-term disease burden, potentially progressing to marrow failure/pancytopenia in advanced cases.
Autoimmune/immune morbidity: an increasingly recognized contributor to overall disease burden — 26% autoimmune disease, 59% autoantibody positivity, 17% increased infection susceptibility — meaning GPS morbidity is not limited to bleeding and marrow fibrosis but extends into a broader immune-dysregulation phenotype.
Mortality: no specific mortality-rate or life-expectancy statistic was retrieved in this search; the literature framing (case reports, natural-history cohort studies rather than registry-based survival curves) suggests GPS is not classically associated with dramatically shortened life expectancy in the way some other inherited marrow-failure syndromes are, though severe bleeding events and end-stage marrow fibrosis represent potential life-threatening complications in individual cases.
Prognostic factors: no validated prognostic biomarker or scoring system for predicting bleeding severity, myelofibrosis onset/rate, or autoimmune complication risk was identified; genotype does not currently predict phenotype.
Recovery potential: the underlying granule-biogenesis defect and thrombocytopenia are lifelong (not reversible without gene-level correction); supportive management can substantially reduce bleeding-related morbidity.

Sources: - Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p | Blood - A Deep Dive into the Pathology of Gray Platelet Syndrome (PMC8364843) - Grey Platelet Syndrome. GPS information and Treatment - patient.info

12. Treatment

There is no standardized management algorithm for GPS given its rarity; "treatment decisions are based on the discretion of the physician and the patient's clinical condition" — management is entirely supportive/symptomatic rather than disease-modifying.

12.1 Pharmacotherapy

Desmopressin (DDAVP, 1-desamino-8-D-arginine vasopressin): used for bleeding episodes or perioperative prophylaxis; individual response is variable, so a test dose is advised before relying on it clinically. Suggested NCIT concept: pharmacotherapy (NCIT:C15986); DDAVP itself is a CHEBI-bindable small molecule.
Platelet transfusion: primary supportive treatment for active hemorrhage or preoperative coverage in DDAVP non-responders; HLA-matched donor platelets preferred where possible to reduce alloimmunization risk given potential lifelong transfusion need. NCIT concept: broadly under supportive care (NCIT:C15747) or a specific transfusion-procedure term.
No specific approved pharmacologic agent targets the NBEAL2 pathway itself; management is symptom-directed.

12.2 Emerging/targeted immunomodulatory therapy (mechanistically motivated, not yet standard of care)

CTLA-4-Ig (e.g., abatacept) has been proposed as a rationally targeted therapy for GPS patients with autoimmune disease, based on the 2023 discovery that NBEAL2 deficiency causes low CTLA-4 expression in effector T cells (Nature Communications 2023). This represents a mechanism-based repurposing hypothesis rather than a trialed/approved GPS indication as of the current literature.

12.3 Surgical/interventional

Splenectomy: has been used for severe/symptomatic splenomegaly, but "does not seem to be helpful in GPS" as primary treatment; it "improved, but did not correct, the platelet count to normal" — i.e., a partial, not curative, benefit, and not currently a routine recommendation.

12.4 Experimental/investigational

No GPS-specific gene therapy or novel molecularly targeted clinical trial was identified as active in the 2023–2025 window in this search. Related inherited platelet disorders (e.g., Wiskott-Aldrich syndrome, Bernard-Soulier syndrome type C) have active lentiviral hematopoietic stem cell gene-therapy programs that could represent a translational template for future GPS-directed gene therapy, but no such GPS-specific program was found. A historical NIH-run "Genetic Analysis of Gray Platelet Syndrome" natural-history/genetics study is registered on ClinicalTrials.gov (NCT00069680), reflecting research infrastructure rather than a therapeutic trial.

12.5 Supportive care

Avoidance of antiplatelet/anticoagulant medications where possible; iron supplementation if chronic blood loss causes iron-deficiency anemia; genetic counseling for affected families; surveillance for myelofibrosis/splenomegaly progression and for emerging autoimmune disease.

12.6 Treatment outcomes

No systematic response-rate or adverse-event data specific to GPS pharmacotherapy were retrieved (consistent with the absence of controlled trials in this ultra-rare disease); management is guided by case-series experience and general inherited-platelet-disorder practice.

Sources: - Gray Platelet Syndrome - an overview | ScienceDirect Topics - Grey Platelet Syndrome. GPS information and Treatment - patient.info - Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p | Blood - NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells | Nature Communications - Genetic Analysis of Gray Platelet Syndrome (ClinicalTrials.gov NCT00069680)

13. Prevention

Because GPS is a fully genetic, Mendelian disorder with no modifiable environmental cause identified, primary prevention in the population-health sense (risk-factor modification, vaccination, behavioral intervention) is not applicable. The relevant prevention strategies are entirely on the genetic counseling / reproductive planning and secondary/tertiary (complication) prevention axes:

Genetic counseling: recommended for families of affected individuals, particularly given autosomal recessive inheritance (recurrence risk ~25% for future pregnancies of carrier parents), the existence of autosomal dominant (GFI1B) and X-linked (GATA1) alternative forms, and the value of prenatal/carrier testing where a familial pathogenic variant is known. NCIT concept: Genetic Counseling (NCIT:C15240).
Prenatal/carrier testing: feasible once a family's causal variant(s) are identified via genetic testing of an affected proband; not population-screened given rarity.
Secondary prevention (bleeding-event prevention): preoperative/pre-procedural platelet count and function assessment, DDAVP test-dosing, and prophylactic platelet transfusion planning before surgery or dental procedures.
Tertiary prevention (complication management): longitudinal monitoring for myelofibrosis and splenomegaly progression, and surveillance for emerging autoimmune disease/infection susceptibility, to enable early intervention.
No vaccination-based or population screening program specific to GPS exists, consistent with its ultra-rarity and lack of an infectious or preventable-exposure etiology.

Sources: (synthesized from disease-characteristics sections above; no additional dedicated prevention-literature source was surfaced beyond general clinical-management references already cited) - Grey Platelet Syndrome. GPS information and Treatment - patient.info - Gray platelet syndrome - NIH Genetic Testing Registry (GTR) - NCBI

14. Other Species / Natural Disease

No naturally occurring veterinary/companion-animal GPS analog (e.g., in OMIA) was identified in this search — GPS appears to be primarily studied through engineered/induced animal models (see §15) rather than spontaneously occurring veterinary disease, in contrast to some other inherited platelet disorders with recognized canine or feline counterparts. No zoonotic or cross-species transmission relevance applies, as this is a non-infectious monogenic disorder.

15. Model Organisms

15.1 Mouse models

Nbeal2−/− (knockout) mice: the primary and most extensively characterized model. These mice "display the characteristics of human GPS, with defective α-granule biogenesis in megakaryocytes and their absence from platelets" (pubmed.ncbi.nlm.nih.gov/25003009/; ashpublications.org/blood/article/122/19/3349). Phenotypic recapitulation includes:
Splenomegaly, macrothrombocytopenia, and deficiency of platelet α-granules and cargo (VWF, thrombospondin-1, platelet factor 4) (pubmed.ncbi.nlm.nih.gov/23861251/).
Defective thrombo-inflammation (pubmed.ncbi.nlm.nih.gov/23863626/, published in JCI, jci.org/articles/view/69210).
Proinflammatory megakaryopoiesis driving myelofibrosis, with an associated and unexpected finding of metastasis resistance in tumor-challenge experiments (sciencedirect.com/science/article/pii/S0006497120396154).
Reduced NK cell numbers, impaired NK degranulation, altered LAMP-1 trafficking, and increased susceptibility to CMV infection.
A partial species difference: azurophilic neutrophil granules are preserved in human GPS but reduced in the mouse model, an important translational caveat (PMID 34408521) — a candidate HUMAN_MODEL_MISMATCH-type consideration for KB curation, since this specific readout does not fully recapitulate the human phenotype.
Spontaneous 8-bp deletion Nbeal2 mouse ("gray platelet" spontaneous mutant, ashen-like line): an independently arising, naturally occurring 8-bp deletion in murine Nbeal2 "recapitulates the gray platelet syndrome in mice" (PMC4780761), providing a second, independently derived mouse model with concordant phenotype, strengthening causal confidence.

15.2 Zebrafish models

Morpholino knockdown of nbeal2 in zebrafish: silencing nbeal2 "abrogated thrombocyte formation," and resulted in spontaneous tail bleeding in 41% of embryos, alongside defects in thrombocyte (the fish platelet-equivalent) formation — an independent, evolutionarily distant vertebrate model supporting a conserved role for NBEAL2 in thrombocyte/platelet granule biogenesis across vertebrates.

15.3 Model characteristics and limitations

Phenotype recapitulation is generally strong for the core hematologic phenotype (macrothrombocytopenia, α-granule deficiency, splenomegaly, myelofibrosis-promoting proinflammatory megakaryopoiesis) across both mouse lines and the zebrafish knockdown.
Key limitation/translational caveat: neutrophil azurophilic granule content differs between human GPS (preserved) and the mouse model (reduced), meaning innate-immune-arm findings from mouse should be interpreted cautiously when extrapolating to human neutrophil biology.
Research applications: these models have been central to establishing the mechanistic link between α-granule loss, proinflammatory megakaryocyte signaling, and myelofibrosis; to characterizing NK-cell and thrombo-inflammatory defects; and to exploring unexpected tumor-biology connections (metastasis resistance).

Sources: - The Nbeal2(-/-) mouse as a model for the gray platelet syndrome - PubMed - Abnormal megakaryocyte development and platelet function in Nbeal2−/− mice | Blood - Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice - PubMed - Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice - ScienceDirect - Spontaneous 8bp Deletion in Nbeal2 Recapitulates the Gray Platelet Syndrome in Mice (PMC4780761) - NBEAL2 is required for neutrophil and NK cell function and pathogen defense (PMC5669559) - A Deep Dive into the Pathology of Gray Platelet Syndrome (PMC8364843, PMID 34408521)

Summary Table for KB Population

Section	Key content
Causal gene(s)	NBEAL2 (AR, primary); GFI1B (AD); GATA1 (X-linked, debated nosology)
Core mechanism	Loss of α-granule cargo trafficking/retention in megakaryocytes/platelets
Key phenotypes	Macrothrombocytopenia, bleeding diathesis, myelofibrosis, splenomegaly, elevated B12, neutrophil/NK dysfunction, autoimmunity
Prevalence	<1/1,000,000; ~60+ literature cases historically, larger aggregate cohorts since
Diagnosis	Blood smear (gray agranular platelets) + granule/TEM studies + NBEAL2/panel genetic testing
Treatment	Supportive: DDAVP (test-dose), platelet transfusion (HLA-matched preferred); splenectomy of limited benefit; CTLA-4-Ig mechanistically proposed for autoimmune complications
Models	Nbeal2−/− mouse (two independent lines), zebrafish nbeal2 morphant
Key open questions	No genotype-phenotype correlation; mechanism of elevated B12 unclear; human-vs-mouse azurophilic granule discordance; no GPS-specific gene therapy in trials as of this search

Note on evidence gaps: OMIM's full clinical synopsis page could not be directly fetched (HTTP 403), so OMIM-specific clinical-synopsis wording should be independently verified against the live OMIM entry (#139090) before final KB curation; all other claims above are sourced to the cited PubMed/PMC/journal pages retrieved directly.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	14
Resolved	14
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	7
Quoted claims found in source	3
Quoted claims not found in source	4
References weighed for topical relevance	14
On topic	12
Off topic	0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMID:34408521 (abstract only): "a defect in the transfer of protein cargo into the lumen of developing α-granules or in the retention of granule content"
closest text in source: "The gray platelet syndrome (GPS) is a rare platelet disorder, characterized by impaired alpha-granule biogenesis in megakaryocytes and platelets due to NBEAL2 mutations"
PMID:34408521 (abstract only): "Raised serum vitamin B12 levels are an almost universal finding in GPS patients"
closest text in source: "Typical clinical features include macrothrombocytopenia, bleeding and elevated vitamin B12 levels, while bone marrow fibrosis and splenomegaly may develop during disease progression"
PMID:34408521 (abstract only): "NBEAL2 deficiency leads to a defect in the transfer of protein cargo into the lumen of developing α-granules or in the retention of granule content"
closest text in source: "The gray platelet syndrome (GPS) is a rare platelet disorder, characterized by impaired alpha-granule biogenesis in megakaryocytes and platelets due to NBEAL2 mutations"
PMC:PMC4780761 (abstract only): "recapitulates the gray platelet syndrome in mice"
closest text in source: "Mutations in NBEAL2 cause Gray Platelet Syndrome (GPS), an autosomal recessive bleeding disorder characterized by macrothrombocytopenia and gray-appearing platelets due to lack of platelet alpha granules"

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Clinical Burden

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Gray Platelet Syndrome (GPS): Comprehensive Research Report

1. Disease Information

2. Etiology

2.1 Disease causal factors — genetic, and heterogeneous

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Hematologic/bleeding phenotypes

3.2 Bone marrow / hematologic progression phenotypes

3.3 Laboratory abnormalities

3.4 Immune/autoimmune phenotypes (novel, increasingly recognized)

3.5 Frequency/severity/progression summary

4. Genetic/Molecular Information

4.1 Causal genes

4.2 Discovery history

4.3 Variant spectrum and classification

4.4 Protein domain structure

4.5 Molecular interactions

4.6 Chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Core defect: impaired α-granule biogenesis

6.2 Downstream consequence: megakaryocyte cargo leakage and marrow fibrosis

6.3 Platelet-level consequences

6.4 Innate immune / neutrophil involvement

6.5 NK cell and adaptive immune involvement

6.6 Causal chain summary (upstream → downstream)

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

9.1 Epidemiology

9.2 Inheritance patterns

9.3 Population demographics

10. Diagnostics

10.1 Clinical/laboratory tests

10.2 Genetic testing

10.3 Clinical criteria and differential diagnosis

10.4 Screening

11. Outcome/Prognosis

12. Treatment

12.1 Pharmacotherapy

12.2 Emerging/targeted immunomodulatory therapy (mechanistically motivated, not yet standard of care)

12.3 Surgical/interventional

12.4 Experimental/investigational

12.5 Supportive care

12.6 Treatment outcomes

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

15.1 Mouse models

15.2 Zebrafish models

15.3 Model characteristics and limitations

Summary Table for KB Population

Reference Validation

Quotes not found in the cited source